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Breathing is generated and controlled by brainstem neurons with several sensory feedback 
loops, where neurotransmission and neuronal membrane excitability play critical roles. Although 
such a neural control provides stable and dynamic breathing activity, central respiration 
depression (CRD) can occur in several diseases and drug misuses, which often leads to severe 
consequences and death. Questions remain open regarding how the neurotransmission and 
cellular excitability are changed in CRD; what cellular and molecular mechanisms underlie the 
changes; and whether they can be corrected with pharmacological agents. This dissertation is to 
address these questions, with two murine models showing characteristic CRD. One is the mouse 
model of Rett syndrome (RTT), and the other is the rat model of morphine-induced CRD. 
Experiments were performed in the models where evidence was obtained with in vivo 
plethysmography and in vitro recording from brainstem neurons. In the RTT model, we studied 
the levels of GABAergic and glycinergic signals of neurons in the hypoglossal nucleus (XII) and 
the dorsal motor nucleus of vagus (DMNV). In the control mice, equal proportions of 
GABAAergic and glycinergic synaptic inhibitions was found in the XII/ DMNV neurons. In the 
RTT model, the deficiency in GABAAergic neurotransmission was more severe, and these cells 
relied more on glycinergic synaptic inhibition. In the morphine-induced CRD model, a decrease 
in cellular excitability was observed in the locus coeruleus (LC) neurons in which the G-protein 
coupled inwardly rectifying K+ (GIRK) channels played a role. The GIRK channel is a 
downstream target of μ opioid receptor (MOR). The activation of MOR by morphine opens the 
GIRK channels to hyperpolarize LC neurons. Thus, GIRK channel blocker cloperastine (CPS), 
an antitussive, was tested. We found that CPS alleviated the morphine-induced CRD, and 





involved inhibitions of GIRK channels in LC neurons, presynaptic glutamatergic neurons, and 
metabotropic glutamate receptors in the presynaptic terminals. Therefore, several molecular 
targets regulating neurotransmission and membrane excitability have been demonstrated to be 
critical for CRD. Pharmacologic targeting on the molecules appears to a novel and promising 
















INDEX WORDS: Respiratory depression, Rett syndrome, Hypoglossal nucleus, Dorsal motor 
nucleus of vagus, GABA, Glycine, Optogenetics, Morphine, μ opioid receptor, GIRK channels, 
























































CENTRAL RESPIRATORY DEPRESSION：INSIGHT WITH MURINE MODELS OF RETT 









Committee Chair:  Chun Jiang 
 




Electronic Version Approved: 
 
 
Office of Graduate Studies 
College of Arts and Sciences 







To my wife Hongmin Yao, who always support, encourage, and take care of me. 
To my mother Xia Sun and my father Shiyan Xing, who love and support me without condition. 

























First and foremost, I would like to thank my advisor, Dr. Chun Jiang. He is really a good 
research advisor and mentor, who has been supporting and pushing me to achieve my Ph.D. 
degree. Without his guidance and help, I would not be where I am today. 
Secondly, I would like to thank my committee members, Dr. Deborah Baro and Dr. Hang Shi 
for their invaluable suggestions and advice helping me to perform better research and improved 
my projects. 
I would also like to thank some faculty members at GSU. Dr. Bingzhong Xue supplied their 
valuable advising when I took my qualifying examination. Dr. Paul Ulrich offered me the 
teaching position and guided my teaching. Dr. Blaustein and Drew helped me be become a 
qualified teaching assistant by showing me many great teaching skills and providing wonderful 
teaching guidance. Thanks Dr. Vincent Rehder for sharing the important scholarship 
information. 
I would also like to thank the staff at GSU. LaTesha Warren and Tameka Hudson have been 
so professional in administrative guidance and assistance. Barry Grant for his help with 
maintenance and repairs. Members from biology core facility, Ping Jiang, Sonja Young, Gemia 
Cameron, Hyek-Kyu Seoh and Debby Walthall, have been very helpful in completing the related 
experiments. Katrina Joyner and Tamiko Brown for their assistance with ordering issues. 
Department of animal resources staff, especially Joey, Kim, Robert, and Courtney, for their 
assistance and advice for animal handling and maintaining. 
I would also like to thank the colleagues and friends I met in GSU, including but not limited 
to Dr. Ningren Cui, Dr. Yang Wu, Dr. Lei Yu, Dr. Weiwei Zhong, Dr. Shuang Zhang, and Dr. 




I acknowledge Brain and Behavior (B&B) Fellowship program for their financial support of 












































TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ........................................................................................................ V 
LIST OF TABLES ...................................................................................................................... XI 
LIST OF FIGURES .................................................................................................................. XII 
ABBREVIATIONS .................................................................................................................. XIII 
1 HYPOTHESES AND SPECIFIC AIMS ............................................................................. 1 
2 INTRODUCTION ................................................................................................................. 4 
2.1 Respiration generation and control .............................................................................. 4 
2.1.1 Respiration controlling neurons .............................................................................. 4 
2.1.2 Network control ........................................................................................................ 6 
2.2 Central respiratory depression ..................................................................................... 9 
2.2.1 Symptoms .................................................................................................................. 9 
2.2.2 Central dysfunction .................................................................................................. 9 
2.3 Central respiratory depression in different models .................................................. 10 
2.3.1 RTT ......................................................................................................................... 10 
2.3.2 Opioid-induced CRD .............................................................................................. 12 
2.4 Cellular mechanism underlying CRD development ................................................. 14 
2.4.1 Neurophysiology and CRD .................................................................................... 15 
2.4.2 Neuronal excitability .............................................................................................. 15 




2.4.4 Respiration-modulatory neurons ........................................................................... 18 
2.5 Molecular substrates underlying CRD ....................................................................... 21 
2.5.1 Synaptic transmission / neuronal excitability ....................................................... 21 
2.5.2 µ-opioid receptor .................................................................................................... 22 
2.5.3 Serotonin receptor .................................................................................................. 23 
2.5.4 Nicotinic acetylcholine receptor ............................................................................ 24 
2.5.5 AMPA receptor ....................................................................................................... 25 
2.5.6 GABA/glycine in brainstem ................................................................................... 25 
2.5.7 Glutamate in brainstem ......................................................................................... 26 
2.5.8 GIRK channel ........................................................................................................ 27 
2.5.9 Pre- / postsynaptic modulation of GIRK channel ................................................. 29 
2.6 Therapeutical potentials .............................................................................................. 31 
2.6.1 Pharmacological approach .................................................................................... 31 
2.6.2 Genetic manipulation ............................................................................................. 32 
2.6.3 Current clinical management ................................................................................ 32 
3 SIGNIFICANCE .................................................................................................................. 34 
4 MATERIAL AND METHODS .......................................................................................... 36 
4.1 Animal ........................................................................................................................... 36 
4.1.1 Rat ........................................................................................................................... 36 




4.2 Plethysmograph Recording ......................................................................................... 36 
4.3 Survival rate.................................................................................................................. 37 
4.4 In vitro electrophysiology ............................................................................................. 38 
4.5 Cell culture and GIRK2/MOR double-transfection ................................................. 39 
4.6 Optogenetic stimulation of GAD-expressing neurons .............................................. 40 
4.7 Single-cell reverse transcriptional PCR ..................................................................... 41 
4.8 Data analysis ................................................................................................................. 42 
5 RESULT 1: CENTRAL INHIBITORY NEURONAL REGULATION OF CRD ........ 43 
5.1 Acknowledgements ....................................................................................................... 43 
5.2 Abstract ......................................................................................................................... 43 
5.3 Introduction .................................................................................................................. 44 
5.4 Results ........................................................................................................................... 46 
5.4.1 Optogenetic stimulation of GAD-expressing neurons inhibit XII / DMNV 
neurons 46 
5.4.2 The opto-inhibition is eliminated with a joint application of GABAA & glycine 
receptor blockers ................................................................................................................... 47 
5.4.3 Miniature IPSCs consisted of GABAA / glycine components ............................... 48 
5.4.4 Single cell RT-PCR showed GABAA / glycine receptor transcriptions ................ 49 
5.4.5 Miniature IPSCs in mice with Mecp2-disruption ................................................. 49 




6 RESULT 2: CENTRAL EXCITATORY NEURONAL CONTROL OF CRD ............. 72 
6.1 Acknowledgements ....................................................................................................... 72 
6.2 Abstract ......................................................................................................................... 72 
6.3 Introduction .................................................................................................................. 73 
6.4 Results ........................................................................................................................... 76 
6.4.1 CPS alleviated morphine-induced respiratory depression ................................... 76 
6.4.2 CPS improved rat survival after morphine overdose ............................................ 77 
6.4.3 CPS counteracted GIRK channel activation after morphine exposure ............... 77 
6.4.4 CPS diminished morphine-induced inhibition of LC neurons ............................ 78 
6.4.5 Pre-/post synaptic mechanisms in regulating LC excitability .............................. 79 
6.5 Discussion ...................................................................................................................... 80 
7 GENERAL DISCUSSIONS .............................................................................................. 103 
8 CONCLUSION .................................................................................................................. 108 








LIST OF TABLES 
 
Table 5.1 RT-PCR primers ........................................................................................................ 69 
Table 5.2 Opto IPSP amplitude (mV) ....................................................................................... 69 
Table 5.3 mIPSC amplitude (Amp., pA) and frequency (Freq., Hz) from control ............... 70 
Table 5.4 mIPSC amplitude (Amp., pA) and frequency (Freq., Hz) from R168X ............... 71 
Table 6.1 Plethysmography data after drug treatment ........................................................... 98 
Table 6.2 Survival data after chemical treatment.................................................................... 99 
Table 6.3 K+ Current in transfected HEK cell ....................................................................... 100 
Table 6.4 Whole-cell current clamp membrane properties .................................................. 101 


























LIST OF FIGURES 
Figure 5.1 Optogenetic activation of GAD-expressing neurons. ............................................ 57 
Figure 5.2 Post-synaptic response of XII and DMNV neurons to optogenetic stimulation. 58 
Figure 5.3 Involvement of both GABAergic and glycinergic synaptic inhibitions in XII and 
DMNV neurons. .......................................................................................................................... 61 
Figure 5.4 Bicuculline and strychnine sensitivities of miniature IPSCs (mIPSCs) of XII 
neurons recorded from mice with and without the R168X mutation in Mecp2. ................... 63 
Figure 5.5 Bicuculline and strychnine sensitivities of miniature IPSCs (mIPSCs) of DMNV 
neurons recorded from mice with and without the R168X mutation in Mecp2. ................... 66 
Figure 5.6 Single cell RT-PCR analysis of GABAA and glycine receptor transcripts in XII 
& DMNV neurons. ...................................................................................................................... 67 
Figure 6.1 Effects of morphine / CPS on whole-body breathing activity. ............................. 84 
Figure 6.2 CPS shifted the survival curve of morphine rightward. ....................................... 86 
Figure 6.3 Effects of morphine/CPS on K+ current in GIRK2/MOR transfected HEK Cells.
....................................................................................................................................................... 88 
Figure 6.4 Morphine / CPS affected the firing activity of LC neuron. .................................. 90 
Figure 6.5 Effects of morphine / CPS on LC firing activities with TTX application. .......... 92 
Figure 6.6 Effects of morphine / CPS on LC membrane properties with CNQX 
administration. ............................................................................................................................ 94 









5-HT 5-hydroxytryptamine or serotonin 
5-HT1A/2A/3/4A/7 serotonin receptor subtype 1A/2A/3/4A/7 
Ach acetylcholine 
aCSF artificial cerebrospinal fluid 
AHP afterhyperpolarization 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
AP5 (2R)-amino-5-phosphonovaleric acid 
Bccl bicuculline 
BötC Bötzinger complex 
ChR channorodopsin 
CNQX 6-cyano-7-nitroquinoxaline-2,3-dione 
CNS central nervous system 
CPS cloperastine  
CRD central respiratory depression 
Cre cre recombinase 
cVRG caudal VRG 
DAMGO (D-Ala2, N-MePhe4, Gly-ol)-enkephalin 
DBH dopamine beta hydroxylase 
DE delayed excitation 
DMNV dorsal motor nucleus of vagus 
DOR σ opioid receptor 




DTN dorsal tegmental nucleus 
E2 expiration 
Early-I early inspiration 
EEG electrocardiogram 
eGFP enhanced green fluorescent protein 
EK K
+ equilibrium potential 
EPSCs excitatory postsynaptic currents 
ER endoplasmic reticulum 
f firing frequency 
GABA γ-aminobutyric acid 
GABAAR GABAA receptor 
GABAARγ2 GABAA receptor γ2 subunit 
GABABR GABAB receptor 
GABAR GABA receptor 
GAD glutamic acid decarboxylase 
GFAP glial fibrillary acidic protein 
GIRK G protein-coupled inwardly rectifying K+ channels 




inhibitory postsynaptic currents 
intraperitoneal 
KF Kölliker-Fuse nucleus 





KOR κ opioid receptor 
LC nucleus of the Locus Coeruleus  
LoxP locus of X-over P1 
MECP2 human methyl CpG binding protein 2 gene 
MeCP2 methyl CpG binding protein 2  
Mecp2 animal methyl CpG binding protein 2 gene 
Mecp2−/Y hemizygous male animal with Mecp2 gene knockout 
Mecp2+/− heterozygous female animal with Mecp2 gene disruption 
Mecp2R168X animal Mecp2 gene with R168X point mutation  
mGluR metabotropic glutamate receptor 
mIPSCs miniature inhibitory postsynaptic currents 
MOR µ opioid receptor 
mPB medial parabrachial nucleus 
nAChRs nicotinic acetylcholine receptors 
NE  norepinephrine 





PFC  prefrontal cortex  
PiCo postinspiratory complex 
PIR post-inhibitory rebound 
Post-I/E1 post inspiration 





RT-PCR reverse transcription polymerase chain reaction 
RTT  Rett Syndrome  
rVRG rostral VRG 





TH tyrosine hydroxylase 
TTX tetrodotoxin 








1 HYPOTHESES AND SPECIFIC AIMS  
As a fundamental process supporting all systemic functions, breathing is generated and 
controlled by brainstem neurons with several sensory feedback loops, where neurotransmission 
and neuronal membrane excitability are likely to play a critical role. Although such a neural 
control provides stable and dynamic breathing activity, central respiration can be compromised 
in several diseases and drug misuses. Such a condition known as central respiration depression 
(CRD) often leads to severe consequences and death. Despite tremendous investigation of the 
CRD over past decades, many questions related to the role of neurotransmission and cellular 
excitability in the CRD remain open. For instance, how does abnormality of brainstem neurons 
lead to CRD? What cellular mechanisms play a role? What molecules responsible for 
neurotransmission and neuronal membrane excitability are involved in CRD? Can these 
molecules be targeted via manipulating neurotransmission and cellular excitability to reverse or 
alleviate CRD? To answer these questions, this dissertation study was designed and performed 
with using electrophysiology, optogenetics, and whole-body plethysmography. My hypothesis is 
that CRD is caused by abnormalities of a few molecules responsible for neurotransmission and 
membrane excitability, finding of which helps not only the understanding of the CRD but also its 
treatment. Two experimental models were chosen to test the hypothesis. Both display clear CRD. 
One of them is a mouse model of the genetic disease Rett syndrome (RTT), and the other is 
opioid overdose. Both involve brainstem neurons that are fully accessible in this lab. Defect in 
inhibitory neurotransmission plays a role in RTT model of mice, while imbalanced excitatory 
neurotransmission / neuronal excitability via μ opioid receptor (MOR) are critical in morphine-
induced CRD rats. Several molecules are involved including γ aminobutyric acid (GABA), 




pharmacologic tools for manipulating these molecules. Using these animal models, we may be 
able to shed insight into the common mechanisms involving defects in neurotransmissions and 
abnormal neuronal excitability in CRD. These may open new fields of research in searching for 
novel therapeutic treatments of several central respiratory disorders in humans.  
Specific Aim: To demonstrate the abnormality of critical molecules that are responsible for 
neurotransmission and/or membrane excitability and attributable to the CRD, and potential 
pharmacological correction. 
Sub Aim 1: To determine inhibitory neurotransmission mediated by distinct GABAergic and 
glycinergic signals in brainstem neurons and their alterations in Mecp2-disrupted mice. 
Experiments were performed in Mecp2-/Y mice to answer the questions: How are the 
inhibitory neurotransmitters GABA and glycine in hypoglossal nucleus (XII) / dorsal motor 
nucleus of vagus (DMNV) neurons affected after methyl-CpG binding protein 2 gene (Mecp2) 
disruption? How do GABAA-ergic and glycinergic signals account for the inhibitory 
neurotransmitters in these brainstem neurons of normal mice? Do the changes in GABAA and 
glycine signaling in XII/DMNV contribute to the neurotransmission abnormality in Mecp2-/Y 
mice?  
Sub Aim 2: To elucidate GIRK channel-mediated neurotransmission in the rat model of 
morphine-induced CRD.  
Experiments were performed in morphine-induced CRD rats with several questions to 
address: Can the blockade of GIRK channels with cloperastine (CPS) alleviate morphine-
induced CRD? Can CPS improve survival of the rats with CRD? What is the potency of CPS for 
GIRK channel inhibition? How does CPS affect LC neuronal excitability and 




presynaptic or both? What presynaptic neurons are involved? How does CPS affect the 









































2.1 Respiration generation and control 
Breathing activity is generated and controlled by brainstem neurons in the medulla oblongata 
and the pons. In the medulla, there are two respiratory centers, i.e., the dorsal respiratory group 
(DRG) and the ventral respiratory group (VRG). The pontine respiratory center is located in the 
dorsolateral region in Kölliker-Fuse (KF), medial parabrachial nucleus (mPB), and the LC. 
Traditionally, the pontine groups are also known as apneustic center and pneumotaxic center. 
These respiratory groups work as a network by highly elaborate neuronal connections, 
generating and regulating the breathing activity including breathing frequency and respiratory 
premotor neuronal output. 
2.1.1 Respiration controlling neurons 
In the medulla, the DRG is located in the nucleus tractus solitarius (NTS) that contains 
mainly inspiratory neurons sending promotor signals to the motor neurons of external intercostal 
muscles and diaphragm. The DRG also receives and integrate sensory afferents from airways and 
peripheral chemoreceptors (Jordan 2001, Song and Poon 2004). DRG neurons can be stimulated 
or inhibited by the signals from pontine neurons. The VRG is located around nucleus ambiguus 
(NA) where there are several subgroups of neurons containing both expiratory and inspiratory 
signals: the expiratory Bötzinger complex (BötC); inspiratory pre-Bötzinger complex (preBötC); 
inspiratory rostral VRG (rVRG); and the expiratory caudal VRG (cVRG) (Shannon and Lindsey 
1987, Smith, Ellenberger et al. 1991, Schwarzacher, Smith et al. 1995, Gerrits and Holstege 
1996). The VRG forms a column in the ventrolateral medulla, also known as the ventral 
respiratory column (VRC). Motor neurons in the VRC send signals to the pharyngeal/laryngeal 




muscles and internal intercostal muscles through the intercostal nerves. The expiratory motor 
drive in cats, rats and rabbits comes from the cVRG only, projecting to abdominal and internal 
intercostal muscles. The BötC, also acts as an expiratory neuronal group, mainly sending 
inhibitory signals to VRG, DRG and phrenic motor neurons (Jiang and Lipski 1990, Bongianni, 
Mutolo et al. 1997, Schreihofer, Stornetta et al. 1999, Bongianni, Mutolo et al. 2010).  
The pontine respiratory groups mostly control the breathing rhythm and patterns. The 
pneumotaxic centers are located in the dorsolateral pons on the caudal side of the inferior 
colliculus, while the apneustic center is known to be in the central area of the lower pons 
(Gautier and Bertrand 1975, Alheid, Milsom et al. 2004). The pneumotaxic centers contain KF 
nucleus and mPB (Song, Yu et al. 2006), that have both inspiratory, expiratory and phase-
spanning cells, and play a role in the switch of respiratory phase from inspiration to expiration 
and respiration reflex. Currently, how the pneumotaxic center interacts with the apneustic centers 
is still unclear. The pneumotaxic center is believed to act as an inhibitory center to the apneustic 
center, sending inhibitory impulses to medullary inspiratory neurons to terminate inspiration and 
increase the respiratory rate (Dutschmann and Dick 2012). The presence of functional apneustic 
center was suggested when its connection to pneumotaxic centers was interrupted with the vagus 
nerves cut, while direct evidence is still lacking. The absence of pneumotaxic center together 
with vagus nerve produces the prolonged inspiratory gasps interrupted by occasional expirations, 
a phenomenon known as apneusis.  
Certain neurons within these two groups are known to be involved in respiration regulation. 
LC is a nucleus located in the caudal midbrain and rostral pons near to the lateral floor of the 4th 
ventricle. As the major pool of noradrenergic signaling in central nervous system (CNS), The LC 




sleep-wake cycle, respiratory regulation, attention, emotion, and anxiety. The excitability of LC 
neurons is critical for the respiratory regulation in different conditions. The LC neuronal 
excitability can be affected by respiratory and metabolic acidosis that has been used as a 
psychiatric diagnostic approach with high CO2 or intravenous lactate to evoke anxiety/panic 
attack. The DMNV is a medullary nucleus of the vagus nerve. The DMNV lies in the ventral to 
the floor of the 4th ventricle. The DMNV motor neurons project to musculus uvulae as well as 
cardiac and laryngeal/pharyngeal muscles. Muscles in the latter two have respiratory rhythmicity 
and are responsible for the maintenance of airway dimension and reflex. The XII is found in the 
dorsal medulla ventral to the DMNV near to the midline of the medulla. The XII contains mostly 
motor neurons sending signals to control the extrinsic and intrinsic muscles of the tongue, 
mediating the movement of tongue includes protruding/deviating. These muscles are respiration-
modulated and play an important part in sleep apneas. LC, DMNV and XII neurons are 
modulated by various neurotransmitters or peptides like GABA, glycine, glutamate, 
acetylcholine (Ach), as well as opioids (Inquimbert, Rodeau et al. 2007, Jin, Cui et al. 2013, 
Oginsky, Cui et al. 2014, McMenamin, Anselmi et al. 2016, Zhang, Johnson et al. 2016, 
Quaresma, Teixeira et al. 2020). Thus, their activities are critical during CRD development.  
2.1.2 Network control 
The neural circuit regulation of respiratory activity is a complicated process. It is known that 
breathing rhythm generation is produced by combined activity of pacemakers and neuronal 
interaction in their network. Respiratory neurons in the VRG interact with each other within 
VRG, also communicating with nuclei in pontine. 
The VRG contains both excitatory and inhibitory respiratory neurons. The inhibitory neurons 




excitatory neurons in the preBötC is glutamatergic, who is responsible for rhythmogenesis 
(Feldman, Del Negro et al. 2013, Janczewski, Tashima et al. 2013), although it has been reported 
that some of the pacemaker neurons do not participate in rhythmogenesis (Del Negro, Morgado-
Valle et al. 2002, Del Negro, Morgado-Valle et al. 2005, Feldman, Del Negro et al. 2013). One 
quarter of the glycinergic neurons in the preBötC shows properties as inspiratory pacemaker 
(Morgado-Valle, Baca et al. 2010), and GABAergic neurons are found within the preBötC with 
inspiratory firing pattern (Kuwana, Tsunekawa et al. 2006). These inhibitory signals within 
preBötC reduce the respiration rhythm without producing apneas (Janczewski, Tashima et al. 
2013), suggesting that rhythmic regulation of respiration involves a postsynaptic inhibition 
within this region. Both rVRG and cVRG are known to utilize glycine for the phasic inhibition 
of the respiratory network (Ezure, Tanaka et al. 2003).  
Once it was believed that, within the respiratory circuitry, the reciprocal inhibition of these 
interneurons were required to produce and maintain the respiration cycle. Although direct 
evidence supporting this scenario is still missing, synaptic inhibitions of these respiratory 
neurons are still critical for central respiratory activity. In rhythmogenesis circuits, the preBötC 
and BötC are the major groups within VRG in shaping respiration patterns. In the BötC, more 
than a half of the neurons is inhibitory, most of which are glycinergic while the rest is 
GABAergic (Winter, Fresemann et al. 2009). The PreBötC has been considered as the key point 
of inhibitory interaction site to communicate with other respiration centers to produce the three-
phase breathing pattern, i.e., inspiration or I, post-inspiration or post-I/E1 and expiration or E2 
(Richter and Smith 2014). The inhibitory communications include: 1) the inhibitory connection 
among inhibitory neurons, pre-inspiratory/inspiratory preBötC cells and BötC augmenting 




(early-I) neurons and BötC post-I cells. Some studies reveal that early-I, post-I and E2 neurons 
are able to form an inhibition ring to regulate respiration (Smith, Abdala et al. 2013).  
It is still unclear how the respiratory groups form the excitatory neuronal circuits. Medullary 
DRG and pontine respiratory groups send excitatory impulses to neurons in BötC, pre-BötC, 
rVRG and cVRG, and these signals are either phasic or tonic (Smith, Abdala et al. 2013). The 
excitatory pre-I/I neurons in preBötC give certain projections onto the premotor rVRG and 
cVRG neurons of phrenic motor neurons, and also project to the motor DMNV/XII neurons. The 
cVRG premotor neurons project to thoracic and abdominal spinal expiratory motor neurons. 
Within the spinal cord, the inter-neuronal circuits regulate respiration motor activities. The BötC 
neurons can be conditionally activated to generate active expiratory activity. Evidence in 
postnatal animal shows that the BötC neurons give excitatory signals on the preBötC region, and 
in return, the preBötC sends both excitatory/inhibitory impulses on BötC cells (Tan, Pagliardini 
et al. 2010, Anderson and Ramirez 2017). Thus, it is reasonable to believe that preBötC acts as 
an excitation trigger to induce the E2 phase. In addition, a recent study proposes the interaction 
between the post-I generator post-inspiratory complex (PiCo) and the preBötC (Anderson, 
Garcia et al. 2016). When applied with GABAA receptor antagonist, the preBötC and PiCo 
synchronize their firing pattern into I phase (Anderson, Garcia et al. 2016). This evidence 
indicates that the inhibition of the neuronal network between PiCo and preBötC is necessary for 
the breathing rhythm maintenance. After abolishing the inhibitory neurotransmission, a dominant 
excitatory input from preBötC onto PiCo can emerge. Together, endogenous inhibitory signals 
overwhelm the excitatory input that originated from preBötC onto PiCo. Even with the evidence, 




necessary to elucidate the mechanisms underlying respiration rhythmogenesis in oscillatory 
networks especially in the CRD condition.  
2.2 Central respiratory depression 
2.2.1 Symptoms 
Respiratory depression also known as hypoventilation, occurs when ventilation is inadequate 
to perform sufficient respiratory gas exchange due to central and peripheral causes. The latter is 
often caused by lung/airway injuries, severe obesity, and neuromuscular/developmental diseases. 
Most cases of respiratory depression are CRD. The causes leading to CRD vary: 1) medical 
conditions, such as physical injury including trauma to the CNS, 2) accidental or intentional 
overdose of chemicals/drugs, like opioids, barbiturates, benzodiazepines, and alcohol, 3) 
voluntary breath-holding like diving training and certain psychiatric diseases, and 4) late stage of 
CO2 retention. The normal breathing rate of a healthy adult is 12–20 breaths/minute with tidal 
volume ~ 500ml, while the symptoms of CRD include slower and shallower breathing with 
breathing rates lower than 8 breaths/minute and a reduction in the tidal volume shows by over 
20% with an increased breathing variation (Barbour, Vandebeek et al. 2004, Hill, Santhakumar 
et al. 2020). The CRD is not synonymous with respiratory arrest, where breathing activity 
completely stops, and death occurs within minutes. The CRD causes an increased concentration 
of CO2 (hypercapnia) and respiratory acidosis. Moderate elevation of CO2 stimulates breathing, 
while extreme hypercapnia inhibits breathing. Besides, the CRD is attributable to systemic 
hypoxia.  
2.2.2 Central dysfunction 
CNS depressant drugs, such as barbiturates, benzodiazepines, ethanol, and other sedatives 




nonselective ligands that binding to various ligand-gated ion channels, including serotonin 
receptor subtype 3 (5-HT3 receptor), glycine receptor, GABAA receptor and nicotinic 
acetylcholine receptor (nAChR). Benzodiazepines binds to the GABAA receptors as agonists to 
control the excitability of neurons. The enhanced inhibitory signals within respiration networks 
are some of the major mechanisms of CRD.  
Multiple anti-nociceptive chemicals, include opioids and its derivatives, can also lead to 
CRD by affecting brainstem neurons including those in the preBötC (Montandon, Qin et al. 
2011, Boom, Niesters et al. 2012). The neurokinin-1 receptor r (NK1R)-expressing preBötC 
neurons are reported sensitive to opioids, which is proved to be responsible for CRD in rats 
(Montandon, Qin et al. 2011). This opioid-induced CRD is likely mediated through the activation 
of MORs on the NK1R - expressing preBötC neurons (Montandon, Qin et al. 2011). The CRD 
can be reversed after the application of serotonin agonists (Manzke, Dutschmann et al. 2009, 
Boom, Niesters et al. 2012). Thus, one of the potential averting effects against the opioid-
induced CRD is to target serotonin receptors in glycinergic preBötC neurons (Manzke, 
Dutschmann et al. 2009). LC neurons are highly sensitive to opioids as well. There is MOR 
expression in the LC. Hyperpolarization occurs when the LC is exposed to MOR agonists 
(Medrano, Santamarta et al. 2017, Enman, Reyes et al. 2019). Therefore, the pharmacological 
investigation to counteract CRD may involve the LC as well.  
2.3 Central respiratory depression in different models 
2.3.1 RTT 
RTT is a neurodevelopmental disorder mostly associated with gene mutations in the methy-
CpG-binding protein 2 (MeCP2) gene on X chromosome, which encodes the MeCP2 




about 0.01% morbidity rate. Boys inherit mutations in human methy-CpG-binding protein 2 gene 
(MECP2) as well but usually died before birth. As transcriptional repressor and activator, 
MeCP2 is associated with maturation of the CNS and formation of synaptic connections. 
Neurological symptoms are firstly observed upon its disruption. The symptoms start from 6 
months of age and deteriorate till the death. Typical RTT symptoms include mental and growth 
retardation, loss of motor function and spoken language, autism-like behaviors, and severe 
breathing disturbances. The breathing disorders in RTT is attributable to the high rate of sudden 
infant death (Del Negro, Koshiya et al. 2002). RTT patients exhibit severe hypoventilation 
interrupted with short hyperventilation (Glaze, Frost et al. 1987). Multiple breathing 
abnormalities can be observed in both daytime and sleep time (Glaze, Frost et al. 1987, Weese-
Mayer, Lieske et al. 2008), like forced breathing, air swallowing, shallow breathing, Biot’s 
breathing, Valsalva’s maneuvers, breath holding and apnea (Kerr, Nomura et al. 2001, Weese-
Mayer, Lieske et al. 2008), as well as abnormalities of cardiorespiratory integration (Katz, 
Dutschmann et al. 2009). 
Studies in mouse model of RTT also suggest an impaired respiration response to hypercapnia 
(Zhang, Su et al. 2011). Mecp2 knockout mice show a reduced sensitivity to mild level of 
hypercapnia with 1-3% CO2 while still sensitive to 6-9% CO2. The affected CO2 chemo-
sensitivity is caused by the abnormal activity of a pH-sensitive K+ channel. The Kir4.1 subunit is 
overexpressed in the null mice leading to an increase in the proportion of this less pH-sensitive 
K+ channel over the more pH sensitive Kir4.1/ Kir5.1 channel. With the defect, CO2 cannot be 
detected by the CNS under mild hypercapnic range (Zhang, Su et al. 2011). Furthermore, 
neuronal sensitivity to hypoxia may also be involved as the preBötC site-specific restoration of 




The hyperexcitation of the KF nucleus and pontine post-I oscillator also been considered as 
major reasons causing respiratory disorders such as periodic breathing, air swallowing and 
apneas, since prolonged post-inspirations were observed (Stettner, Huppke et al. 2007, Abdala, 
Dutschmann et al. 2010). In Mecp2-null mice, the occasional central apneas may be due to the 
dysregulation of post-I activity via disrupting the inspiration initiation. At age of 2-month 
postnatal, a prolonged expiration phase with apnea was reported in Mecp2-null mice, while no 
significant changes were found during inspiratory phase (Stettner, Huppke et al. 2007, Weese-
Mayer, Lieske et al. 2008). This could lead to reduced breathing frequency (Viemari, Roux et al. 
2005). In RTT, abnormality of KF neurons contributes an in-coordinated glottal closure during 
swallowing, which may contribute to breathing apnea (Abdala, Toward et al. 2016). Therefore, 
these authors believe that the apnea problem in RTT together with upper airway dysregulations 
may be due to the disrupted central respiratory network: 1) with a decreased excitatory input 
onto inspiratory neurons, and 2) an overly increased excitatory input onto expiratory neurons. 
2.3.2 Opioid-induced CRD 
Opioid-induced CRD refers to the breathing depression syndrome that often occurs with 
opioid overdose or misuse and is the major reason of opioid-induced death. Opioid-induced CRD 
is a common side effect during opioid drug application. The symptoms of opioid-induced CRD 
include decreased breathing frequency, reduced respiratory tidal volume and depressed minute 
ventilation. In human, the respiration rate can be reduced as low as 8 breaths/min, leading low O2 
saturation (<85%) with high arterial CO2 concentration, accompanied with the decreased 
ventilatory response to hypercapnia/hypoxia (Boland, Boland et al. 2013). Researchers are 
interested in identifying how opioid disrupts respiratory rhythmogenesis and respiratory motor 




bodies. The brainstem houses respiratory neuronal networks and CO2 chemoreceptors, while the 
carotid bodies contain O2 and proton chemoreceptors. Three potential mechanisms may underlie 
the opioid-induced CRD: 1) inhibition of the preBötC networks for rhythmic breathing, 2) 
disruption of respiratory regulation including O2 and CO2 chemoreception, and 3) suppression of 
brainstem premotor output by bulbospinal neurons in the ventral and dorsal respiratory groups. 
But it is debatable as to which playas a predominant role in the opioid-induced CRD, and 
whether they can be counteracted with pharmacologic approach.  
Currently, naloxone types of MOR antagonists are the only effective therapeutics 
(Yousefifard, Vazirizadeh-Mahabadi et al. 2020). However, the usage of the MOR antagonists as 
preventive drugs has problems, as they tend to induce withdrawal responses, and antagonize 
nociception and other therapeutic objectives. Another option for the treatment of opioid-induced 
CRD is respiratory stimulants. Dahan et al. (Dahan, van der Schrier et al. 2018) have recently 
reviewed and analyzed most respiratory stimulants in opioid-induced CRD treatment, including 
doxapram, GAL021, ampakines, 5-hydroxytryptamine (5-HT) receptor agonists, D1-dopamine 
receptor agonists, phospodiesterase-4 inhibitors, the endogenous peptide glycyl-glutamine, and 
thyrotropin-releasing hormone. The authors conclude that none of these experimental drugs are 
adequate for therapeutic use in opioid-induced CRD (Dahan, van der Schrier et al. 2018). Such a 
conclusion also points out an alarming reality that there are no therapeutic agents to prevent 
opioid-induced CRD at all, as naloxone is not suitable for the purpose. Thus, it is necessary to 





2.4 Cellular mechanism underlying CRD development 
Changes in cellular structure can lead to changes in cellular function and ultimately systemic 
behavior. Before CRD symptoms occur, cellular changes already manifest, some of which may 
or may not be compensated enough to cover symptoms (Wang, Reyes et al. 2013). Several 
changes in neuronal morphology include altered dendritic spine morphology, decreased soma 
size, reduced number of synapses (Armstrong, Dunn et al. 1995). Some are related to 
transcriptional and translational levels of intracellular skeletal structures (Merriam, Millette et al. 
2013). Evidence indicates that chronic treatment with morphine induces a decreased density of 
dendritic spines (Liao, Lin et al. 2005). Studies also suggest that there is reduced cell volume, 
even with no increase in cell death (Marchetto, Carromeu et al. 2010), which is attributable to the 
insufficient brainstem development seen in RTT as well. The reduced cell volume affects 
dendritic spine morphology, which is related to the expression of α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) and n-methyl-d-aspartate (NMDA) receptors together with 
Ca2+ homeostasis in the dendrites (Merriam, Millette et al. 2013).  
Studies indicate that impairment of Mecp2 may impair neuronal differentiation and cell fate 
by affecting senescence (Kim, Hysolli et al. 2011, Squillaro, Alessio et al. 2012). This suggests 
that there may be structural abnormalities in the brainstem respiratory neurons of RTT patients. 
However, reactivation of the Mecp2 gene during adulthood restored normal function in Mecp2-
null mice, indicating that the basic structure and connections in the brain appear intact, and only 
the impairment may be functional (Guy, Gan et al. 2007). Research in opioid-induced CRD 
reveals that tolerance and withdrawal symptoms may be due to the neuronal structural changes 




is lost quickly during withdrawal (Zhilenko, Khoroshilova et al. 1989). Which makes overdose 
induced CRD occur again in people who misuse opioids in a little while after withdrawal. 
2.4.1 Neurophysiology and CRD 
Like structural components of neurons, cellular dysfunction has been discovered in various 
disease models with CRD. Significant concerns about cellular dysfunction are the changes in 
neuronal intrinsic properties, synaptic activity, and information integration. The output of a 
neuron depends on normal synaptic connections and intrinsic membrane properties. The neuronal 
output affects systemic function and behavior. Changes in the neuronal output can lead to 
abnormal behavior including breathing abnormality. Electrophysiological techniques such as 
whole-cell patch clamp, are commonly used to study neuronal functions, allowing the study of 
electrophysiological properties. The electrophysiological properties of neurons contain 
information of neuronal excitability, synaptic activity, and intrinsic membrane properties. The 
latter includes passive membrane properties, active membrane properties, and repetitive firing 
properties. 
2.4.2 Neuronal excitability  
Neuronal excitability is known as the ability of a neuron to fire action potentials. The more 
firing, the higher is the excitability. Defected membrane properties with underlying ion channels 
affect neuronal excitability and are often associated with diseases. Alterations in neural 
excitability lead to changes in neuronal communication, gene expression, and neuronal plasticity. 
Studies on pain have shown that there is a group of nerve fibers capable to elicit action potentials 
with lower threshold of stimulus, contributing to the pain symptom, especially in inflammation 
and diabetes-associated allodynia (Hong, Morrow et al. 2004, Wang, Strong et al. 2007). 




currents (Hu, Carrasquillo et al. 2006). Similarly, studies show increased excitability in dorsal 
root ganglion neurons is associated with inflammatory pain (Hu, Carrasquillo et al. 2006, Tan, 
Donnelly et al. 2006). Changes in firing patterns towards phasic firing have been implicated in 
epilepsy. The elevated glutamate level, decreased inhibitory inputs and bias towards 
hyperexcitation are linked to epilepsy (Treiman 2001, Barker-Haliski and White 2015). The 
epilepsy mouse model highlights changes that lead to increased hyperpolarization and increased 
sensitivity to excitatory inputs (Shah, Anderson et al. 2004, Jung, Jones et al. 2007). Pyramidal 
neurons of hippocampus, that with burst firing properties, shift from 3% to 48% due to changes 
in Ca2+ sensitivity and K+ currents (Sanabria, Su et al. 2001). Changes in intrinsic properties 
have been linked to neuronal output and function (Zhang and Linden 2003). Some well-studied 
examples of membrane properties changes have been proved to be attributable to pathology 
symptoms including Alzheimer’s disease as well (Mantegazza, Gambardella et al. 2005, Kim, 
Carey et al. 2007). Many studies have been focused on the mechanisms of changes in neuronal 
firing patterns. These changes are linked to normal homeostasis as well as pathological states.  
The normal regulation of whole-scale oscillations is critical. Neurons need to coordinate all 
membrane properties and synaptic activity in order to create functional outputs. Variability in 
electroencephalogram (EEG) waveforms indicating desynchronization has been found in autism 
spectrum disorders (Sun, Grutzner et al. 2012). Studies demonstrate that the fast phasic firing is 
important for regulating network timing (Klausberger, Magill et al. 2003), and an increased 
glutamate together with a reduced GABA leads to the neuronal hyperexcitability in autism 




2.4.3 Intrinsic membrane properties 
During the morphine treatment, the membrane property of neurons in KF and preBötC show 
significantly hypoexcitable (Varga, Reid et al. 2020), with inhibitions of LC, XII and DMNV 
(May, Dashwood et al. 1989, Hajiha, DuBord et al. 2009). Neuronal overexcitation is very rare 
in opioid application but not none (Thomas, Corson et al. 2019). Membrane property changes are 
altered in Mecp2 mutant mice, resulting a disruption in excitation/inhibition balance underlying 
CRD development (Calfa, Li et al. 2015, Banerjee, Rikhye et al. 2016). Hyperexcitation in the 
hippocampus, brainstem, and substantia nigra is the major electrophysiological property change 
associated with CRD in RTT (Zhang, He et al. 2008, Gantz, Ford et al. 2011). Neuronal 
excitability changes are regionally different. For example, the forebrain of Mecp2-null mice 
shows hypoexcitation (Dani, Chang et al. 2005). Brainstem neurons include LC and XII cells are 
hyperexcitable with increased firing activity in response to current injections and increased 
spontaneous firing activity (Taneja, Ogier et al. 2009, Zhang, Cui et al. 2010, Jin, Cui et al. 
2013). Other altered membrane properties include increased action potential threshold and 
inward rectification, action potential morphology, spike frequency adaptation, delayed 
excitation, and after hyperpolarization (Zhang, Cui et al. 2010). These changes indicate that basal 
level of neuronal activity is altered as well as responses to synaptic signals. Mechanisms 
underlying changes in membrane properties largely depend on changes in protein expression of 
the corresponding properties. 
Passive membrane properties belong to intrinsic membrane properties, which are electrical 
characteristics of neurons that determine the electrical signaling capabilities. The properties 
include capacitance, resting membrane potential and input resistance. Capacitance refers to the 




size of the cell based on this property, because a large cell has a large capacitance and requires 
more current to change the resting membrane potential. Input resistance describes the 
relationship between current and voltage. According to the Ohm’s law, V= I×R, an injected 
current will change the membrane potential of a cell. Similarly, membrane resistance is 
dependent on the opening/closing status of ion channels, as well as the number of ion channels 
located on the membrane of the cell. Capacitance and membrane resistance together describe 
time constant of neurons, which is the time that takes for membrane potential to reach a steady 
state in response to stimulate. 
With the passive membrane properties, a neuron responds to current injection in a linear 
fashion. Once it passes a certain threshold, the neuron starts to generate action potentials. Then 
the membrane properties of the cell are described as active membrane properties, which indicate 
the neuron responses after the neuron starts firing. Active membrane properties include firing 
frequency (f), afterhyperpolarization (AHP), rheobase, postinhibition rebound (PIR), bursting 
activity, spike frequency adaptation (SFA) and delayed excitation (DE). The latter three are also 
known as repetitive firing properties. 
2.4.4 Respiration-modulatory neurons 
There are multiple neurons involved in respiration regulation in CRD. We here are focused 
on three specific neurons that are highly correlated in CRD development both in RTT model and 
opioid-induced CRD model. 
2.4.4.1 Neurons in the locus coeruleus  
LC is a nucleus located in the posterior area of the rostral pons in the lateral floor of the 4th 
ventricle. LC neurons project to various regions including cortex, brain stem, cerebellum, 




in CNS that performs excitatory effects on most of its projection sites. Functions of the LC 
include arousal and sleep-wake cycle, attention, emotion, behavioral and cognitive control, and 
respiratory regulation.  
LC neurons are modulated by GABA, glycine, glutamate, Ach, and opioids. As the source of 
NE, the excitability of LC and afferent/effect neurotransmissions are critical for respiratory 
regulation in different conditions. Previous studies from our lab have shown that both the 
GABAergic inhibition and acetylcholine (Ach) modulation in the LC area are significantly 
reduced in Mecp2-null mice, which lead to neural hyper-excitation (Jin, Cui et al. 2013, Oginsky, 
Cui et al. 2014). These changes contribute to the impaired norepinephrine (NE) synthesis/release 
within the LC region and a decreased NE content in the brainstem. Reduced expressions of 
dopamine beta hydroxylase (DBH) and tyrosine hydroxylase (TH) were observed in LC neurons 
(Roux, Panayotis et al. 2010, Zhang, Su et al. 2010). Our current study indicates that besides 
GABA signaling, glycine signaling also shows reduction on LC, and these two neurotransmitters 
performed a mutual compensatory regulation of LC excitability. Our study also shows that 
morphine inhibits the firing activity of the LC neurons via modulating membrane properties and 
altering presynaptic glutamatergic neurons as well as glutamate release from their synaptic 
terminals, which contribute to opioid-induced CRD. These defects in neurotransmission and LC 
excitability can be alleviated by blockade of GIRK. After the opioid administration, the 
increased activity of the LC neurons contributes to the symptoms of withdrawal. The α2 
adrenergic receptor agonist clonidine is used to decrease adrenergic neurotransmission from LC 




2.4.4.2 Neurons in the dorsal motor nucleus of vagus 
The DMNV is a cranial nucleus for the vagus nerve. The DMNV is located in the medulla 
that lies ventral to the floor of the 4th ventricle. It mostly serves parasympathetic vagal functions 
in the lungs, airways, heart, gastrointestinal tract, and thoracic/abdominal vagal innervations 
include broncho-constriction, gland secretion. The DMNV also raises the branchial efferent 
motor fibers innervating musculus uvulae and laryngeal/pharyngeal muscles activity. Upper 
airway regulation is critical under the CRD condition. The DMNV shows high expression level 
of nAChRs (Vivekanandarajah, Waters et al. 2019), and the neuronal excitability is proved to be 
affected by cholinergic signals (Quaresma, Teixeira et al. 2020). Also, genetic defects of choline 
acetyltransferase in DMNV neurons leads to over-bronchoconstriction in mice (Lai, Su et al. 
2016). Site specific administration of opioid agonist in the DMNV cause clear CRD (May, 
Dashwood et al. 1989). Besides, decreased serotonin 1A receptor (5-HT1A) and serotonin 2A 
receptor (5-HT2A) immunoreactivity levels were found in sudden infant death syndrome (SIDS) 
kids with CRD (Ozawa and Okado 2002). Study also found altered 5-HT innervation and/or 
uptake in the DMNV contribute to abnormal modulation of respiration in RTT patients 
(Paterson, Thompson et al. 2005). Inhibitory neurotransmissions including GABA and glycine 
are critical factors in maintaining DMNV excitability (Inquimbert, Rodeau et al. 2007, 
McMenamin, Anselmi et al. 2016). Considering the function and various neuronal regulations, 
the DMNV is a potentially important target in CRD studies. 
2.4.4.3 Hypoglossal neurons  
The XII is another cranial nerve nucleus in the medulla. It is located between the DMNV and 
the midline of the medulla. The XII sends motor signals to control the extrinsic and intrinsic 




regulations participate in breathing, speaking, swallowing, and talking. Together with DMNV, 
neuronal excitability of the XII is proved to be affected by cholinergic signals (Quaresma, 
Teixeira et al. 2020). The XII site specific microinjection of carbachol activates acetylcholine 
receptors and reverses CRD by increasing respiratory rate (Brandes, Stettner et al. 2011). 
Another study reveals that the activation of MOR reduces motor output from the XII, and further 
affects the upper airway function causing breathing disorder (Hajiha, DuBord et al. 2009). 
Previous studies from our lab have shown that the glycinergic synaptic transmission can be 
facilitated after activating the α1-adrenoceptor, and excited XII via both pre- / postsynaptic 
mechanism (Jin, Cui et al. 2013), while opto-stimulation of NEergic terminals had no effect on 
XII excitability in TH-ChR-Mecp2-/Y double-transgenic mice (Zhang, Johnson et al. 2016). 
Opioids depress XII motoneuronal output by presynaptic inhibition mechanism, which can be 
counteracted by AMPA receptor modulator ampakines (Lorier, Funk et al. 2010). Other 
antagonistic neuropeptides, like methionine-enkephalin, were found reduced in the XII from 
RTT patients (Saito, Ito et al. 2001). Taken together, the XII is a critical site in regulating 
respiratory pattern in CRD.  
2.5 Molecular substrates underlying CRD 
2.5.1 Synaptic transmission / neuronal excitability 
Besides the intrinsic membrane properties, changes in synaptic connections also contribute to 
changes in neuronal excitability in CRD. Classical neurotransmitters such as glutamate, GABA, 
and glycine can change membrane excitability in receiving cells. The major excitatory 
neurotransmitter in the CNS is glutamate, which causes excitatory postsynaptic potentials 
(EPSPs). GABA is the major inhibitory neurotransmitter in the brain causing inhibitory 




plays a more important role in the lower brainstem and the spinal cord, though it can be found in 
sparse areas of the forebrain (Baer, Waldvogel et al. 2009). All of these three neurotransmitter 
systems act on ionotropic receptors causing fast responses on the postsynaptic cells. Glutamate 
also bind to metabotropic glutamate receptor (mGluR) to affect neuronal excitability by 
presynaptic modulation of neurotransmission. GABA also bind to GABA subtype B (GABAB) 
receptor. Both mGluR and GABAB receptors produce their biological effects by opening GIRK 
channels. 
2.5.2 µ-opioid receptor 
Opioid receptors are G protein-coupled receptors, which include 5 subtypes: MOR, σ-opioid 
receptor (DOR), κ-opioid receptor (KOR), ζ-opioid receptor (ZOR) and nociception receptor 
(NOR). MOR has been considered as the major one that interacts with opioids leading to CRD 
symptom. MOR is widely expressed in brain, spinal cord, peripheral neurons, and intestinal tract. 
In the CNS, MOR is found in nucleus accumbens, cortex, nucleus amygdala, olfactory bulb, 
nucleus of solitary tract, LC, and superficial dorsal horn of spinal cord.  
MOR can bind with endogenous opioid peptides like endomorphins, endorphins, dynorphins 
and enkephalins; also, can be activated by agonists like morphine, fentanyl and D-Ala2, N-
MePhe4, Gly-ol]-enkephalin (DAMGO). After activation, MOR leads to various effects include 
analgesia, sedation, euphoria, pupil constriction, reduced gastrointestinal motility and CRD. The 
CRD is the major cause of opioid leading death.  
Short-term activation of MOR changes neuronal excitability via suppression of presynaptic 
release of GABA. After the application of fentanyl, a decreasing of glutamate and increasing of 
GABA release were observed in hypothalamus (Pourzitaki, Tsaousi et al. 2018). These changes 




respiratory abnormality in opioid administration. Long-term or high-dose use of opioids leads to 
mechanisms of tolerance include downregulation of MOR gene expression, which reduces the 
number of receptors on the cell membrane. As a result, higher concentration of opioids is needed 
to reach the same level of cellular responses. A sudden stop or reduction of opioids leads to 
withdrawal symptoms, like drug craving, anxiety, vomiting, diarrhea, and sweating. The 
withdrawal response is related to the abnormality of norepinephrine system. During the opioid 
withdrawal, activation of the LC adrenergic neurons is observed, and α2 agonists can be used to 
reduce the symptoms (Imani 2011). 
Studies have been concentrated on the CRD induced by MOR activation, whereas research 
on the relationship between MOR and CRD in RTT is limited. One study reveals that MOR gene 
can be silenced under epigenetic control of Mecp2, leaded to the altered expression of MOR in 
multiple brain regions including cerebellum (Hwang, Song et al. 2009). This could give us a 
starting point to investigate the MOR signaling under respiratory regulation in RTT. Currently, 
naloxone is still the most efficient chemical to reverse morphine-induced CRD by binding to 
MOR to stop the following cellular responses. 
2.5.3 Serotonin receptor  
5-HT receptors are found in the central and peripheral nervous systems. The 5-HT receptor 
modulate the release of many neurotransmitters, including GABA, glutamate, epinephrine / 
norepinephrine, acetylcholine, dopamine, and various hormones. 5-HT receptors can be divided 
into 7 families of G protein-coupled receptors except for the 5-HT3 receptor, a ligand-gated ion 
channel. 5-HT3 receptors activates an intracellular second messenger cascade to produce an 
excitatory or inhibitory response. Studies have investigated the activity and manipulation of 5-




specific behavioral including breathing depression in RTT (De Filippis, Nativio et al. 2014). 
Human study on 11-year-old RTT girl co-treated with 5-HT1A receptor agonist and 5-HT 
reuptake inhibitor reduced CRD (Ohno, Saito et al. 2016). Animal studies show that 5-HT 
agonists increase respiration drive force by activating 5-HT1A, 5-HT7, and 5-HT4A receptors 
(Oertel, Schneider et al. 2007). But there are no significant effects when using the 5-HT1A 
receptors agonist buspirone and the 5-HT4A receptors agonist mosapride to counteract opioid-
induced CRD in humans (Lotsch, Skarke et al. 2005). The lack of efficiency in human use may 
be due to a low potency / lower brain concentrations achieved in human (van der Schier, 
Roozekrans et al. 2014), which indicates 5-HT receptors could still be potential target in treating 
opioid-induced CRD.  
2.5.4 Nicotinic acetylcholine receptor 
nAChR are widely found in the central and peripheral nervous system, muscle, and many 
other tissues of many organisms. It can be activated by acetylcholine and the agonist nicotinic. It 
serves the motor nerve-muscle communication in neuromuscular junction, also transmits signals 
between synapsis within sympathetic and parasympathetic nervous system. In CNS, the opening 
of nAChR allow cations, like Na+, K+ and Ca2+, flow cross the pore, which regulate the release of 
neurotransmitters in classical synaptic transmission so as paracrine transmission (Racke, 
Juergens et al. 2006). Previous study from our lab shows the α5-subunit of nAChR was increased 
as the α7-subunit was decreased in Mecp2-null mice, accompanied with an enhanced nAChR 
modulated GABA input to the LC (Oginsky, Cui et al. 2014). Activation of α4β2 nAchR by 
ABT-594 and varenicline counters opioid-induced CRD without affecting analgesia effect (Ren, 
Ding et al. 2020). These lines of evidence indicate that nicotinic acetylcholine receptor is 




2.5.5 AMPA receptor 
AMAP receptor is an ionotropic receptor which is activated by glutamate. The AMPA 
receptor usually acts as heterotetrameric receptor with the combination of 4 subunits: GluA1, 
GluA2, GluA3 and GluA4. The AMPA receptor is permeable to cation like Na+, K+ and Ca2+. 
Upon the agonist binding, EPSPs follows to depolarize the postsynaptic cells affecting neural 
plasticity and synaptic transmission. Both effects are known to be involved in CRD. Within the 
hippocampus region in RTT mice, an overly increased excitatory signal is found due to the 
abnormal synaptic trafficking of AMPA receptors (Li, Xu et al. 2016). Human study shows that 
the defect of AMPA receptor GluA2 subunit disrupts the glutamatergic neurotransmission, 
leading to RTT-like features with CRD (Salpietro, Dixon et al. 2019). Animal studies show that 
ampakine CX717 increases the breathing rate by activating the AMPA receptors specifically in 
the preBötC region. There are studies confirming that ampakine compounds are able to elevate 
the breathing rate together with the slope of the ventilation responses to carbon dioxide, which 
eventually raises respiration driving force during opioid-induced CRD (Ren, Poon et al. 2006, 
Oertel, Felden et al. 2010). Possibly, drugs that interfere with AMPA receptor may prove useful 
to prevent opioid- and non-opioid-induced CRD. 
2.5.6 GABA/glycine in brainstem 
The inhibitory neurotransmission includes two neurotransmitters: GABA and glycine. GABA 
is the predominant transmitter in inhibitory neurons of the brain while glycine typically exists in 
the spinal cord, brainstem, and retina. After bind to GABAA receptor and glycine receptor, 
respectively, IPSPs occur to affect the neuronal excitability. A lot of attention has been given to 
the involvement of GABA in the shift of excitation/inhibition balance in the development of 




Mecp2-null mice in several different nuclei, including, but not limited to the LC, NTS, and KF 
(Jin, Cui et al. 2013, Abdala, Toward et al. 2016, Chen, Di Lucente et al. 2018). Extensive 
studies on GABA neurons in RTT models have not been performed, but some studies looking at 
subclasses of GABA neurons have provided insight into how Mecp2 disruption affects their 
activity. One of the primary ways to classify GABA neurons is to examine their expression of 
GABA receptors, enzymes for GABA synthesis and other coexisting proteins. For instance, a 
major subgroup of GABA neurons expresses parvalbumin (PV), calcitonin, and somatostatin. 
The PV neurons appear to be the most widespread throughout the CNS. The PV cells in Mecp2-
null mice are hyperexcitable (Wydeven, Marron Fernandez de Velasco et al. 2014). Selective 
deletion of Mecp2 in either PV or SOM neurons also causes RTT-like phenotypes (Ito-Ishida, 
Ure et al. 2015). It has been reported that patients taking prescription opioids together with 
gabapentin have an increased risk of opioid-induced CRD (Gomes, Juurlink et al. 2017). The 
specific activation of 5-HT1A receptor leads to a dephosphorylation of type α3 glycine receptors, 
induces disinhibitions of excitatory and inhibitory neurons to alleviate opioid-induced CRD 
(Manzke, Niebert et al. 2011). 
2.5.7 Glutamate in brainstem 
Glutamate is the most abundant excitatory neurotransmitter in the vertebrate nervous system. 
Glutamate interacts with four types of receptors: AMPA receptor, NMDA receptor, mGluR, and 
kainate receptors. The last one is similar in respects to AMPA receptor but less abundant. 
Glutamate also serves as precursor for the metabolic synthesis of GABA, and the activation of 
NMDA receptor requires co-binding of glycine and glutamate. Considering the role of glutamate 
in CRD, there is a study proving that glutamate content was decreased in hippocampus region in 




correlated with global reductions of GABA (El-Khoury, Panayotis et al. 2014). Another study 
confirmed a glutamate-induced glutamate release pattern is attributable to abnormal neuronal 
excitability in Mecp2-/Y mice (Balakrishnan and Mironov 2018). It has been reported that the 
glutamatergic system shows an increased NMDA receptor density in RTT girls younger than 8-
year of age, while a reduction of NMDA receptor density was observed in girls older than 10 
(Blue, Naidu et al. 1999). Site specific alteration of NMDA receptor expression in RTT mouse 
models confirms these findings (Blue, Naidu et al. 1999). Esketamine, a non-competitive NMDA 
receptor antagonist, has been shown to be usable in countering CRD in RTT (Jonkman, van 
Rijnsoever et al. 2018). The altered synaptic trafficking of AMPA receptors contributes to the 
hyper-excited synaptic activity in hippocampus in RTT (Li, Xu et al. 2016), and AMPA receptor 
modulator has been applied to reverse CRD (Ren, Ding et al. 2009, Sultan, Gutierrez et al. 2011). 
A recent study suggests that the major mechanism underlying opioid-induced CRD involves 
MOR-mediated inhibition of presynaptic Ca2+ channels within the preBötC area (Ramirez, 
Burgraff et al. 2021). The excitatory neuronal signal to the XII is regulated by AMPA receptors. 
After activation of the MOR by DAMGO, a reduced inspiratory XII motor output can be 
observed due to an inhibition of presynaptic excitatory glutamatergic neurotransmission (Lorier, 
Funk et al. 2010). 
2.5.8 GIRK channel 
One common ion channel target of GPCRs is the GIRK channel, which is expressed widely 
throughout the brain. The GIRK channel is a group of K+ permeable ion channels that are a part 
of the larger Kir channel family. Kir channels pass inward K
+ currents at membrane voltages 




than the outward K+ current that passes through the channel above EK. This is in contrast with 
other K+ channels that primarily only allow current to flow outward.  
The four isoforms of GIRK channels are GIRK1, GIRK2, GIRK3, and GIRK4. GIRK 
channels 1-3 are found primarily in the CNS, while GIRK4 is primarily located in the heart. The 
GIRK channels 1 and 2, often expressed together, are the primary subunits expressed in the brain 
(Liao, Jan et al. 1996). GIRK channels form tetramers and typically as heterotetramers (Kofuji, 
Davidson et al. 1995). GIRK2 is the only subunit that can form homotetramers (Lesage, 
Guillemare et al. 1995). There exist splicing variants of GIRK2, GIRK 2a, b, and c (Wei, Hodes 
et al. 1998, Luscher and Slesinger 2010). There are also GIRK1 splicing variants, although they 
have not been studied as well. Splicing variants for GIRK3 and GIRK4 are still unknown.  
The subcellular location of GIRK channels depends on the subunit. In pyramidal neurons, 
GIRK2a and GIRK2c proteins show overlapped expressing locations. Unlike GIRK2c, located 
throughout the entire neuron, GIRK2a is mostly found on the soma and proximal dendrites 
(Marron Fernandez de Velasco, Zhang et al. 2017). The GIRK1d splicing variant expression was 
shown to reduce the currents of other GIRK channels when co-expressed (Steinecker, Rosker et 
al. 2007). In addition, substantia nigra and VTA neurons do not express GIRK1 channels, but 
express GIRK2a-GIRK2c and GIRK2a-GIRK3 combinations, which are less sensitive to Gβγ 
again emphasizing the importance of subunit expression patterns. GIRK channel density in 
axons, soma, and dendrites differ (Ponce, Bueno et al. 1996). Thus, different GIRK channel 
isoforms have differential subcellular expression patterns, and that activation of different 




2.5.9 Pre- / postsynaptic modulation of GIRK channel 
The GIRK channel has the ability to pass inward K+ ions, but the main contribution is still 
efflux of K+ ions upon activation as most neuronal resting membrane potentials are above the EK. 
GIRK channel activation leads to hyperpolarization and inhibition of a neuron. Changes in basic 
level of GIRK channel activity affects resting membrane potential by 2-8 mV in hippocampal 
and dorsal raphe neurons (Luscher, Jan et al. 1997, Llamosas, Ugedo et al. 2017). GIRK 
channels regulate both pre- and postsynaptic cells. The presynaptic regulation of GIRK channels 
is known in conjunction with auto-receptors, regulating the neurotransmitter release from the 
releasing cell. These presynaptic auto-receptors bind the neurotransmitter located on axon 
terminals, where the GIRK channels serve as negative feedback mechanisms, decreasing or 
inhibiting a further release of the neurotransmitter from the synaptic terminal. Another 
mechanism by which GIRK channels cause self-inhibition is through dendro-denritic interactions 
or autaptic transmission (Bacci, Huguenard et al. 2004).  
GIRK channel activation on postsynaptic cells leads to inhibition as well. The GIRK channel 
activation has a slow sustained effect as compared to ionotropic receptor activation. 
Communication is not always one way though. Postsynaptic cells can inhibit neurotransmitter 
release from presynaptic cells by activation of GIRK channels via retrograde signaling. Common 
retrograde signaling molecules include endocannabinoids, nitric oxide, or CO (O'Dell, Hawkins 
et al. 1991, Wilson and Nicoll 2001). GIRK channels have been implicated in many different 
physiological phenomena as well as pathophysiological conditions. They play an important role 
in epilepsy, opioid addiction, and Parkinson’s disease. GIRK2 knockout mice develop seizures 
and have reduced pain alleviation mediated by opioids (Signorini, Liao et al. 1997, Mitrovic, 




CPS is a blocker of GIRK channels. The effects of CPS application can be either excitatory 
or inhibitory depending on the location of GIRK channels. In additional to GIRK channels, CPS 
may bind to histamine receptors, sigma receptors, and sodium-glucose transporters (Oranje, 
Gouka et al. 2019), which may also contribute to the inhibition of the CNS by this drug. If the 
binding proportions of each type are unbalanced, the effect on one protein may overwhelm the 
other. After knocking down mRNA expression of GIRK or knocking out GIRK channels, the 
necessity of GIRK channels during CPS-mediated respiration improvement can be investigated. 
The LC region has a significant amount of GIRK channel expression (Kawano, Zhao et al. 
2004). Therefore, blocking GIRK channels directly on LC cells should stimulate these cells. 
Opposite effects of GIRK channel inhibition by CPS were found between RTT CRD mice and 
morphine-induced CRD rats. Previous studies in this lab suggest that the effect of CPS was 
inhibitory in LC cells in RTT mice, where hyperexcitability is predominant (Johnson, Cui et al. 
2020). The CPS-enhanced GABA transmission overwhelms the stimulatory effect of CPS.  
In rat model of morphine-induced CRD, hypo excitability is seen in LC neurons. Whereas 
CPS promotes the glutamate signal to depolarize morphine-inhibited LC neuron in morphine-
induced CRD rats in our research. The inhibition of LC cells in RTT mice may help reduce LC 
excitability and correct the defective NE synthesis via GABA signaling (Johnson, Cui et al. 
2020), while it is interesting to know the facilitation effects of CPS on glycinergic signaling to 
reverse CRD in RTT. In RTT respiratory depression, the excitatory effect of CPS could enhance 
the glycine signal onto LC by 1) blocking GIRK on presynaptic glycinergic neurons and/or 2) 
facilitating a pre-presynaptic glutamatergic signaling onto the presynaptic glycinergic cells. Even 
though multiple targets including GIRK channel have been tested (Ren, Ding et al. 2009, 




Ding et al. 2019, Imam, Kuo et al. 2020), further investigation of GIRK-mediated neuronal 
excitability and neurotransmission may lead to alternative approaches to brainstem neurons to 
counteract CRD. 
2.6 Therapeutical potentials  
2.6.1 Pharmacological approach 
Several pharmacological interventions, includes NE reuptake blocker, or the interventions to 
increase the biogenic amine were able to alleviate the breathing problems in RTT mice (Viemari, 
Roux et al. 2005, Medrihan, Tantalaki et al. 2008). Study applied the 5-HT1A receptor agonists 8-
OH-DPAT and F15599 also correct irregular breathing pattern and reduce apnea by decreasing 
expiratory neuron activity (Kline, Ramirez-Navarro et al. 2007, Turovsky, Karagiannis et al. 
2015). Another approach has been done with the administration of 5-HT re-uptake blockers that 
is proved to be able to increase the expression level of MeCP2 proteins (Voituron, Menuet et al. 
2010). Currently, naloxone types of MOR antagonists are the only effective therapeutics for 
opioid-induced CRD (Yousefifard, Vazirizadeh-Mahabadi et al. 2020). But several problems 
cannot be ignored that the usage of the MOR antagonists as preventive drugs tend to antagonize 
the desired nociception, also induce withdrawal responses. Respiratory stimulants could be a 
good option for the treatment of opioid-induced CRD. A variety of respiratory stimulants 
targeting on multiple receptors/pathways have been reviewed and analyzed in opioid-induced 
CRD treatment, including doxapram, GAL021, ampakines, 5-HT receptor agonists, D1-
dopamine receptor agonists, phospodiesterase-4 inhibitors, the endogenous peptide glycyl-
glutamine, and thyrotropin-releasing hormone. None of these experimental drugs are adequate 
for therapeutic use, although they revealed the potentials in opioid-induced CRD treatment 




2.6.2 Genetic manipulation  
Beside the pharmacological intervention, genetic strategy is always an option to treat CRD. 
In RTT, the mutation of Mecp2 contributes to the CRD symptom. The functions of MeCP2 are 
activating and repressing various downstream genes. The mutations of Mecp2 produce abnormal- 
or un-function MeCP2 proteins. One approach is to stabilize the expression level of MeCP2 
protein from the normal Mecp2 allele by using serotonin re-uptake blockers, which mean to 
maintain the sufficient amount of normal MeCP2 protein. Another way is taking advantage of 
the X chromosome inactivation mechanism (Voituron, Menuet et al. 2010). It could be 
reasonable if we are able to turn off the mutate allele of MECP2 while turn on the normal one on 
the other X chromosome, which could reduce the CRD in RTT patients. Genetic therapy for 
treating CRD in opioid-induced CRD is very limited. One research group found the Galnt11 
gene that transcripts GALNT11, an N-acetylgalactosaminyltransferase, is responsible for 
exporting of DOR from endoplasmic reticulum (ER) to cell membrane within preBötC complex, 
and the deletion of Galnt11 shows a partial reversion of opioid-induced CRD (Bubier, He et al. 
2020).  
2.6.3 Current clinical management  
Respiration stimulants are commonly used in CRD treatment, which mean to stimulate the 
CNS to enhance the respiration drive with certain level of bronchi-dilating effect. The anti-CRD 
effect of respiratory stimulants may not be related to the reasons for CRD, but the application of 
stimulants is mostly accompanied by specific agonists/antagonists. The usage of specific 
agonists/antagonist is based on the patient history of drug usage, which has been proved 
efficient. But the situation of CRD patients can be complicated as multiple drugs may be used 




chemicals. It is possible to worsen the situation due to the side effects from the combination 
usage of anti-RD medicines. Ventilator is also a clinical option both in emergent CRD and 
consistent respiration maintaining condition. Ventilator forces air flow in/out of lungs to enable a 
passive respiration activity in CRD patients, which maintains the adequate intake of O2 and 





































CRD is commonly seen in several deadly diseases and drug misusage. The neurobiological 
mechanisms of the CRD, and its relationship with neurotransmission and neuronal excitability 
are still poorly understood. Also, it is necessary to demonstrate the CRD in multiple 
experimental models where different cellular mechanisms may be in action, so that these cellular 
mechanisms and the identified molecules or cell signaling pathways may be targeted to 
counteract CRD. 
RTT is a neurodegenerative disease, mainly affecting female kids with an incidence rate of 1 
out of 10,000 worldwide. CRD including hypoventilation with irregular breathing is the most 
serious symptom in the RTT patients, attributable to the high rate of sudden death. Mutations of 
the MECP2 gene result in more than 90% of RTT cases. It has been reported that a defected 
GABAergic signal plays a part in the disease, leading to over-excitation of respiratory neurons, 
which is responsible for the respiratory rhythm disruption in RTT (Medrihan, Tantalaki et al. 
2008, El-Khoury, Panayotis et al. 2014, Zhong, Cui et al. 2015). In the brainstem, neurons utilize 
both GABA and glycine as inhibitory neurotransmitters for neuronal activity regulation. 
However, whether and how glycine signaling plays a role in RTT CRD remain elusive. We plan 
to use the Mecp2−/Y (Mecp2-null) male mouse model and performed in vitro electrophysiological 
recordings from brainstem XII/DMNV neurons to understand the inhibitory neurotransmission 
changes in RTT. CRD is also a major adverse effect of opioid drug misusage, which causes a 
loss of large numbers of lives worldwide (Kobelt, Burke et al. 2014). The opioid-induced CRD is 
primarily mediated by MOR that can be blocked by naloxone types of drugs (Imam, Kuo et al. 
2018). However, the usage of them as preventive drugs has problems, as they tend to antagonize 




naloxone types of drugs are only therapeutics today, there is an urgent need for the understanding 
of cellular/molecular mechanism underlying CRD in opioid usage condition, so that effective 
therapeutics may be developed to reverse or alleviate opioid-induced CRD by means of a novel 
approach other than opioid receptor blockade. MOR is coupled to G-proteins and β-arrestins. 
The former regulates GIRK channels to affect the neuronal excitability, and the latter is coupled 
to adenylyl cyclase. GIRK channel targeting avoids the MOR that may induce unwanted side-
effects as the MOR is widely expressed in the CNS. As some antitussives act on brainstem 
mechanisms, it is possible to identify the non-opioid antitussive drugs that act on neuronal 
excitability via GIRK channels instead of MOR, with relative specificity to the brainstem to 
suppress the opioid-induced CRD.  
Thus, we designed this project to reveal defective patterns of GABAergic and glycinergic 
inhibitory neurotransmissions in RTT model, and GIRK channel inhibition by an antitussive 










4 MATERIAL AND METHODS 
4.1 Animal 
All animal experiments were conducted in accordance with the National Institutes of Health 
(NIH) Guide for the Care and Use of Laboratory Animals and were approved by the Georgia 
State University Institutional Animal Care and Use Committee.  
4.1.1 Rat 
The experiments were performed on WT rats. The wildtype Sprague Dawley rat (Crl: CD, 
Outbred, Charles River Laboratory, Kingston, NY) were used in this study. Both male and 
female animals were evenly used in the present study. 
4.1.2 Mice 
The GAD-ChR transgenic mice were generated by cross-breeding the strain of GAD2-Cre 
mice (Gad2tm2(cre)Zjh/J, Jackson Laboratory SN: 010802) with the ChR2-eGFP-LoxP strain 
(B6;129S-Gt(ROSA)26Sortm32(CAG-COP4*H134R/EGFP)Hze/J, Jackson Laboratory SN: 
012569). R168X point mutation: female heterozygous Mecp2R168X point mutation mice (strain 
name: Mecp2tm1.1Jtc/SchvJ|B6J; 129S6.Mecp2R168X, Jackson Laboratory, SN: 024990) were crossbred 
with wildtype C57BL/6 males to produce the hemizygous Mecp2R168X mutant male mice. A 
genotyping PCR was done to the offspring according to the protocol provided by the Jackson 
Laboratory. Only male animals were used in the present study.  
4.2 Plethysmograph Recording  
All rats were 7~8 weeks old and weighed about 170 g. After the pre-injection, on the 3rd day, 
one conscious and free moving rat was placed into the plethysmography recording chamber. The 
animal was given a 10-minute settle down time in the recording chamber, then a 20-minute 




injected with 10 mg/kg morphine sulfate and put back to recording chamber right away, recorded 
the breathing for 20~30 minutes, followed by a subcutaneous (s.c.) injection with 30 mg/kg CPS 
and placed the rat back to recording chamber right after the injection. Then a 5-hour recording 
will be done with a 10-minute break for every 60 minutes. The tidal volume and breathing 
frequency will be recorded by measuring the pressure changes between the animal chamber and 
a reference chamber with a force-electricity transducer (PanaVise Products, Inc. Nevada). To 
have close estimation of the tidal volume (VT), a series of calibration was conducted by 
converting recorded signals to tidal volume according to a series of measurements with known 
volumes of air injection to the plethysmograph chamber in a similar time period to each breath. 
The chambers were perfused with normal air at a flow rate of ~50 ml/min. The variation of tidal 
volume, variation of breathing frequency and breathing minute ventilation will be calculated. 
During the 10 minutes break, the recording rat will be put back to the housing cage for food and 
water intake. 
Breathing activity was collected and analyzed with Clampfit software (Molecular Devices) 
and calculated from at least 100 successive breathing cycles. 
4.3 Survival rate  
For our survival curve test, all experimental rats were orally pre-treated with cloperastine in 
drinking water for 7 continuous days. The dosage of oral cloperastine treatment is 30 mg/kg/day, 
the control group was given with normal drinking water. After 7 days oral treatment of CPS, rats 
were i.p. injected with morphine sulfate on the 8th day and the survival outcomes will be 
recorded: either the tested animal is survived or dead. A series of doses of morphine sulfate will 




170 mg/kg. One rat was injected with one dose, and no animal were tested more than one 
injection regardless of the survival outcomes. The outcomes were recorded as survival or death. 
4.4 In vitro electrophysiology 
Whole cell voltage-clamp and current-clamp studies were performed on cells visualized 
using a near-infrared charge-coupled device camera. Patch pipettes were pulled with a Sutter 
pipette puller (model P-97, Novato) with a resistance of 4-6 MΩ. The slices were perfused with 
the external solution continuously with bubbling of 95% O2 and 5% CO2 at 34°C.  
For transfected HEK cell patch recording, the pipette solution for voltage clamp recordings 
contains (in mM) 130 KCl, 20 NaCl, 5 EGTA, 5.46 MgCl2, 2.56 K2ATP, 0.3 Li2GTP, 10 
HEPES, pH=7.4, mOsm=313. The aCSF contains (in mM) 20 KCl, 140 NaCl, 0.5 CaCl2, 2 
MgCl2, 10 HEPES, pH=7.4, 318 mOsm. The eGFP positive cells will be used for patch clamp. 
The I-V protocol from -120 mV to 100 mV with delta change of +20 mV and a ramp protocol 
from -100 mV to 100 mV were performed to confirm positive GIRK2 transfection; morphine-
increased K+ current can be used to confirm positive MOR transfection. A continuous recording 
protocol with -80 mV holding for 1500ms out of 2000ms was recorded to test the K+ current 
amplitude level.  
For brain slice whole-cell patch recording, the internal (pipette) solution for current clamp 
recordings contained (in mM): 130 potassium-gluconate, 10 KCl, 10 HEPES, 2 Mg-ATP, 0. 3 
Na-GTP, and 0. 4 EGTA (pH 7.30, 285 mOsm. The aCSF solution for current clamp contained 
(in mM): 124 NaCl, 3 KCl, 1. 3 NaH2PO4, 2 MgCl2, 10 d-glucose, 26 NaHCO3, 2 CaCl2, 0.4 
ascorbic acid (pH 7.40 bubbled with 95% O2 and 5% CO2). The internal (pipette) solution for 




HEPES, 5 Mg-ATP. The aCSF for brain slice voltage clamp contains (in mM): 124 NaCl, 2.5 
KCl, 1.3 MgSO4, 2.4 CaCl2, 1.2 NaH2PO4, 11 glucose, 25 NaHCO3.  
Whole-cell voltage clamp experiments were performed at a holding potential of −70 mV. To 
be able to only record AMPA current in brain slice whole-cell voltage clamp experiments, the 
synaptic currents were blocked with the NMDA receptor antagonist DL-AP5 (10 μM), the 
voltage-gated sodium channel blocker TTX (0.5 μM), and the Cl- current was blocked by 
bicuculline (20 μM) and strychnine (2 μM). The LY341495 (20 μM) was applied before CPS (20 
μM) treatment to block mGluR and increase glutamate release into synapsis; then LY341495 was 
replaced by CPS to test if there were any further changings of mEPSCs.  
A perfusion speed of 5 ml/min was used to make sure the diffusion of chemicals is quick and 
sufficient. A minimum of 15 min was allowed between each treatment to eliminate any 
desensitization, and no slice was exposed to the drug more than 2 times. The cell capacitance 
was measured at the beginning of the recording, and any recordings where the series resistance 
changed during the experiment were rejected from further analysis. Recordings were amplified 
with an Axopatch 200B amplifier (Molecular Devices, Union City, CA) with a 2 kHz filter, 
digitized at 10 kHz, and collected with the Clampex 10.0 software (Molecular Devices). 
4.5 Cell culture and GIRK2/MOR double-transfection  
Rat G-protein coupled inwardly rectifying K+ channel subfamily J member 2 (GIRK2) cDNA 
(GenBank accession No. XM_039088045), rat mu-opioid receptor (MOR) cDNA (GenBank 
accession No. XM_008758731) and enhanced green fluoresce protein (eGFP) cDNA (GenBank 
accession No. YP_003162718) were gifted from Dr. Henry A. Lester and Dr. Norman Davidson 




expression vector pcDNA3.1 (Invitrogen) and used for HEK293 expression without cRNA 
synthesis. Correct construction was confirmed with DNA sequencing (GENEWIZ). 
The HEK293 cells were kindly provided by Dr. Deborah Baro (Georgia State University). 
HEK293 cells were cultured at 37 °C / 5 % CO2 according to supplier recommendations. For 
electrophysiological studies of transfected HEK cell: Day 1, cells were cultured in 35mm culture 
dish for 24 hours to have 50~80% confluence. Day 2, the amount of 5.0 μg target DNA, 0.5 μg 
GFP DNA and 8 μl LipofectamineTMReagent (Gibco BRL, Cat No. 18324-012, 2mg/ml) will be 
added into 500 μl Opti-MEM medium (Gibco, Cat No. 31985-070, 1X). Add the mixture to the 
cultured cell and incubated at 37 °C for 4 hours, withdraw the solution and add 2 ml DMEM with 
10% FBS, incubated at 37 °C for 18 hours. Day 3, detach the transfected HEK cell and 
transferred onto 5 X 5 mm glass slice (pre-coated with Ploy-L-Lysine, Sigma, P4832). Cells 
were cultured for 24~36 hours before patch clamp recording. Succeed transfected HEK cells 
were confirmed by positive eGFP together with morphine-increased K+ current. 
4.6 Optogenetic stimulation of GAD-expressing neurons 
GAD-expressing neurons were detected in brain slices with eGFP expression using 
fluorescence microscopy in excitation at 470 nm and emission at 535 nm. Opto-stimulation was 
performed by using a xenon light source with high-speed switcher (Lambda GD-4, Sutter 
Instruments, Novato, CA). The light source was connected to the incident-light illuminator port 
of the Zeiss Axioskop 2 microscope (Carl Zeiss AG) and delivered blue light through a 470-490 
nm bandpass filter. The 10ms pulse trains were triggered by the Digi-timer D4030 pulse 
generator (Digitimer Ltd, UK). The latency of light-evoked action potentials was measured from 




4.7 Single-cell reverse transcriptional PCR  
Reverse transcription of the single-cell contents obtained from XII or DMNV neurons after 
each patch clamp recording and put under -20°C freezer until the reverse transcription was 
performed. The reverse transcription was done within 12 hours after obtained the single-cell 
contents. The first-strand cDNA synthesis was done using the high-capacity cDNA reverse 
transcription kit (Applied Biosystems, LOT 00862966) according to the manufacturer's 
instructions. The reverse transcription product was kept at -20°C until PCR was performed. PCR 
primers for the target genes were designed with the computer software programs Primer3 and 
Primer-BLAST (NIH) (Table 5.1). PCR product lengths were ~200bp to not confuse them with 
primer dimers. Three microliters of reverse transcription product were loaded into an Eppendorf 
tube with PCR solution containing 10 μl of 5× green GoTaq flexi buffer, 2 μl MgCl2, 1 μl of 10 
mM dNTP mix, 1 μl of 10 mM forward and reverse primers, 0.25 μl of GoTaq polymerase, and 
diluted to 50 μl with nuclease-free water. The thermal cycling program was set to the initial 
denaturation for 5 min at 95°C for one cycle. The denaturation, annealing, extension cycles were 
done at 95°C for 45 s, 58°C for 45 s, and 72°C for 1 min, respectively, for 35 cycles. A final 
extension cycle was done at 72°C for 10 min. Thirty microliters from the second PCR reaction 
was run on a 2% agarose gel containing ethidium bromide. Gels were imaged using Alpha 
Innotech Imaging System (Alpha Innotech, Santa Clara, CA). Presence of receptor subunits in 
the XII / DMNV cell was defined by having a band at the correct size, regardless of strength. 
Cells that had bands with smearing, possible degradation, or positive glial fibrillary acidic 




4.8 Data analysis   
Clampfit 10.7 software (Molecular Devices) and Mini Analysis Program 6.0.7 (Synaptosoft 
Inc.) were used to analyze the electrophysiological data. RT-PCR data were analyzed by ImageJ 
1.8.0-112 software (National Institutes of Health) based on their average value from all 
experiments, in each of which 3-4 samples were tested. Statistical analysis was performed using 
the two-way ANOVA with Fisher’s post hoc test, one-way ANOVA with Bonferroni’s post hoc 
test, and/or the two-tailed Student’s t-Test (IBM SPSS Statistics 26.0.0.0). The LD50 of morphine 
was calculated by Hill equation, survival histogram comparison was analyzed by Log-rank 

























5 RESULT 1: CENTRAL INHIBITORY NEURONAL REGULATION OF CRD 
Published as “Xing, H. Cui, N. Johnson, C. M. Faisthalab, Z. Jiang, C. Dual synaptic 
inhibitions of brainstem neurons by GABA and glycine with impact on Rett syndrome. J Cell 
Physiol, 2021. 236(5): p. 3615-3628.” 
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5.2 Abstract 
RTT is a neurodevelopmental disease caused by mutations in the MECP2 gene. People with 
RTT show breathing dysfunction attributable to the high rate of sudden death. Previous studies 
have shown that insufficient GABA synaptic inhibition contributes to the breathing 
abnormalities in mouse models of RTT, while it remains elusive how the other inhibitory 
neurotransmitter, glycine, is affected. We find optogenetic stimulation of GAD-expressing 
neurons produced GABAergic and glycinergic postsynaptic inhibitions in the XII and the 
DMNV. By sequential applications of 10µM bicuculline and 1µM strychnine, such inhibition 
shows ~44% GABAAergic and ~52% glycinergic in XII, and ~49% GABAAergic and ~46% 
glycinergic in DMNV in mice without Mecp2 disruption. Measuring miniature IPSPs (mIPSCs) 
in these neurons, the GABAAergic and glycinergic current amplitudes are ~47% and ~49% in 
XII neurons, and ~48% and ~50% in DMNV neurons, respectively. Single-cell PCR indicated 
transcripts of GABAA receptor γ2 subunit (GABAARγ2) and glycine receptor β subunit (GlyRβ) 
were simultaneously expressed in these cells. In Mecp2R168X mice, proportions of GABAAergic 
and glycinergic mIPSC amplitudes became ~28% vs. ~69% in XII, and ~31% vs. ~66% in 




were significantly decreased in XII / DMNV, so as the transcripts of GABAARγ2 and GlyRβ. 
These suggest that inhibitory neurons in the medulla produce toughly equal GABAAergic and 
glycinergic synaptic inhibitions of XII and DMNV neurons. With Mecp2 disruption, the XII / 
DMNV neurons rely more on glycinergic synaptic inhibition. 
5.3 Introduction 
RTT is a neurodevelopmental disease seen almost exclusively in girls who have 6 to 18 
months of apparently normal development after birth, followed by occurrence and progressive 
deterioration in motor, learning and other behavioral functions (Gold, Krishnarajy et al. 2018). 
Other symptoms include breathing abnormalities, midline hand position, unusual eye 
movements, sleep disturbances, seizures, etc. (Mellios, Feldman et al. 2018). The breathing 
disorders are attributable to the high rate of sudden death. 
Mutations in the MECP2 gene encoding methyl-CpG binding protein 2 underlie almost all 
cases of RTT and some variant forms of the condition (Enikanolaiye, Ruston et al. 2020). The 
cytogenetic location of this gene is the long arm of the X chromosome at position 28. The 
MeCP2 is a critical regulator for activity of various gene (Sbardella, Tundo et al. 2020, Schmidt, 
Zhang et al. 2020), and exists in cells throughout the body, particularly abundant in neurons 
(Pejhan, Siu et al. 2020). Mutations in the MECP2 gene cause disruptions of normal functions of 
neurons and glia cells in the brain. One of the most common Mecp2 mutations associated with 
Rett syndrome is Mecp2R168X point mutation leading to a premature peptide without the methyl-
CpG binding domain. In the mouse model of RTT with Mecp2R168X, a number of RTT 
phenotypes have previously been shown, including respiratory, neuromuscular, and behavioral 




Breathing and several other autonomic functions are generated or controlled by brainstem 
neurons, including those in the XII and the DMNV. The XII houses somatic motor neurons 
innervating the extrinsic and intrinsic muscles of the tongue. They control the upper airway 
dimension, tongue movements, speech, and swallowing. The XII neurons are modulated by 
respiratory neuronal networks with regular respiratory bursting activity and provide changes in 
tongue muscular tones according to the breathing rhythm (Petukhova, Ponomareva et al. 2018, 
Subramaniam, Bawden et al. 2018). The DMNV contains visceral motor neurons constituting the 
major vagus efferents. It serves for most parasympathetic motor functions in the heart, the 
gastrointestinal tract, and the urogenital system.  
Previous studies in mouse and rat models of RTT have shown that several groups of 
brainstem neurons are overly excited, including those in the ventral respiratory group 
(Yamanouchi, Kaga et al. 1993, Calfa, Li et al. 2015, Wu, Zhong et al. 2016, Oginsky, Cui et al. 
2017). The hyper-excitability of the brainstem neurons is related to deficiency in GABAergic 
synaptic inhibition (He, Chen et al. 2014, Abdala, Toward et al. 2016, Anderson, Garcia et al. 
2016), which as well as several RTT-types of breathing abnormalities can be improved after the 
administration of GABA re-uptake blockers or GABA receptor agonists (Fogarty, Smallcombe et 
al. 2013, Jin, Cui et al. 2013, Zhong, Johnson et al. 2016). Glycine is another inhibitory 
neurotransmitter playing a role in the spinal cord and the retina (Fogarty, Smallcombe et al. 
2013, Poria and Dhingra 2015, Zhou, Han et al. 2016, Petukhova, Ponomareva et al. 2018, 
Waldvogel, Biggins et al. 2019). Glycine plays an inhibitory role in the brainstem, whereas it is 
still unclear how the Mecp2 disruption affects glycine signaling here. More importantly, if 
neurons adopt both GABAergic and glycinergic synaptic inhibitions, they may gain a survival 




which may occur in the RTT model. To test this hypothesis, we performed these studies. We 
chose the Mecp2R168X mice to study how the GABAergic and glycinergic synaptic inhibitions are 
affected as this mouse model is closer to human RTT patients than the Mecp2-null models. We 
chose the male mice because: The hemizygous mutant male shows similar symptoms compared 
to symptomatic heterozygous females (Shah and Bird 2017, Ribeiro and MacDonald 2020). The 
heterozygous female mice show a large variability in RTT-like symptoms because of the 
numerous asymptomatic heterozygous females (Johnson, Cui et al. 2015). Also, the hemizygous 
male are considered as a common model for this disease (Ribeiro and MacDonald 2020). 
5.4 Results 
5.4.1 Optogenetic stimulation of GAD-expressing neurons inhibit XII / DMNV neurons  
Transverse brainstem slices were obtained from GAD-ChR mice. GFP-positive neurons were 
found in several brainstem areas. At the level of the obex (Figure 5.1A & B), these GFP-positive 
neurons were seen in the area ventrolateral to the XII nucleus (Figure 5.1C, D1 & D2). In 
contrast, cells in the XII and DMNV showed no GFP fluorescence (Figure 5.1D1 & D2). In 
whole-cell voltage clamp, a large outward current was produced in these GFP-positive cells with 
opto-stimulation (Figure 5.1E1 & E2). The current reversed its polarity at near 0mV (Figure 5.1F1 
& F2), indicating that the current is conducted by cations confirming the expression of ChR in 
these cells.  
Whole-cell recording from the XII / DMNV neurons (Figure 5.2A) showed that the opto-
stimulation produced strong hyperpolarization and inhibition of neuronal firing activity (Figure 
5.2B1 & C1). The hyperpolarization reversed its polarity at near the Cl- reversal potential (Figure 




suggesting that the inhibition is post-synaptic after opto-stimulation of ChR-expressing neurons, 
which is likely to be inhibitory postsynaptic potentials (IPSPs).  
5.4.2 The opto-inhibition is eliminated with a joint application of GABAA & glycine receptor 
blockers  
Because of the Cl- reversal potential in GAD-ChR transgenic mice, we expected that the opto 
IPSPs recorded in XII and DMNV neurons to be mediated by GABAA receptors. To our surprise, 
we found that the IPSPs were not eliminated after application of a high concentration of 
bicuculline (Bccl, 10 µM) (Figure 5.3A1 & B1). The remaining portion of the IPSPs was totally 
abolished when 1 µM strychnine (Stcn) was added to the perfusion solution (Figure 5.3A1 & B1). 
Similarly, the opto IPSPs were attenuated but not blocked by 1 µM Stcn alone (Figure 5.3A2 & 
B2). They were completely blocked with 10 µM bicuculline added after Stcn (Figure 5.3A2 & 
B2). These results indicate that the ChR-expressing neurons release both GABA and glycine with 
opto-stimulation, and these neurotransmitters produce postsynaptic inhibitions of XII and 
DMNV neurons by activations of GABAA and glycine receptors.  
To address the question as to whether XII and DMNV neurons rely on one of the 
neurotransmitters more than the other, we performed quantitative studies by blocking GABAA 
and glycine receptors sequentially. With application of 10 µM Bccl first followed by 1 µM Stcn, 
the opto IPSPs were suppressed by 49.1 ± 7.4% (means ± s.e.) and 48.2 ± 6.3%, respectively, in 
XII neurons (Bccl: 5.4±1.1mV, Stcn: 5.2±1.1mV, n=9), and by 51.7 ± 4.0% and 44.4 ± 3.9%, 
respectively, in DMNV neurons (Bccl: 5.8±1.1mV, Stcn: 4.9±0.8mV, n=9) (Figure 5.3C) (Table 
5.2).  
With application of 1 µM Stcn first followed by 10 µM Bccl, the opto IPSPs were suppressed 




5.2±0.8mV, n=8), and by 47.6 ± 2.2% and 47.4 ± 2.2%, respectively, in DMNV neurons (Stcn: 
6.2±0.9mV, Bccl: 6.1±1.0mV, n=11) (Figure 5.3D) (Table 5.2). 
5.4.3 Miniature IPSCs consisted of GABAA / glycine components  
In voltage clamp, miniature IPSCs were studied in these two groups of neurons after 
chemical synaptic isolation with AP5, DNQX and TTX (to remove glutamatergic synaptic 
excitations and spontaneous firing activity). The cells were recorded at a holding potential near 
to the EK with Cs
+ in the pipette solution to get rid of K+ current and GABAB receptor 
contribution. Under this condition, mIPSCs were recorded from XII and DMNV cells (Figures 4 
& 5). In the control mice, the baseline amplitude and frequency of these mIPSCs in XII neurons 
were 33.2 ± 2.2 pA and 8.2 ± 1.2 Hz (n=24), respectively. They were 35.0 ± 3.4 pA and 6.5 ± 0.9 
Hz in DMNV cells (n=18), respectively. Neither the mIPSC amplitude nor the frequency was 
significantly different between the XII and DMNV neurons (Amplitude: XII, mean=33.2±2.2pA, 
n=24; DMNV, mean=35.0±3.4pA, n=18; P=0.65. Frequency: XII, mean=8.2±1.2Hz, n=24; 
DMNV, mean=6.5±0.9Hz, n=18; P=0.34. Student’s t-Test). 
With 10 µM Bccl treatment first followed by 1 µM Stcn, the mIPSC amplitude was reduced 
by 52.8 ± 1.6% and 43.1 ± 2.4% (Bccl: 18.8±1.6pA, Stcn: 15.5±1.5pA, n=9), the frequency was 
suppressed by 52.7 ± 6.6% and 46.6 ± 6.7% (Bccl: 7.7±1.4Hz, Stcn: 5.3±0.5Hz, n=9), 
respectively (Figure 5.4A1 & C; Table 5.3) in XII neurons. In DMNV with the same sequence of 
blocker treatments, the mIPSC amplitude was reduced by 46.7 ± 2.0% and 51.4 ± 2.3% (Bccl: 
18.4±2.7pA, Stcn: 18.9±2.8pA, n=9), the frequency was reduced by 57.2 ± 1.0% and 41.8 ± 
1.1%, respectively (Bccl: 3.7±0.7Hz, Stcn: 2.3±0.5Hz, n=9) (Figure 5.5A1 & C; Table 5.3). 
With 1 µM Stcn first followed by 10 µM Bccl, the mIPSC amplitude was reduced in XII neurons 




while the frequency was lowered by 47.0 ± 6.1% and 48.9 ± 6.4%, respectively (Stcn: 
2.3±0.5Hz, Bccl: 2.6±0.6Hz, n=15) (Figure 5.4A2 & D; Table 5.3). In DMNV, the mIPSC 
amplitude was decreased by 50.8 ± 2.6% and 46.3 ± 2.5% (Stcn: 16.5±2.4pA, Bccl: 15.0±2.3pA, 
n=9), and the frequency was reduced by 47.6 ± 3.4% and 49.2 ± 3.9%, respectively (Stcn: 
3.6±0.7Hz, Bccl: 4.0±0.8Hz, n=9) (Figure 5.5A2 & D; Table 5.3). 
5.4.4 Single cell RT-PCR showed GABAA / glycine receptor transcriptions 
If XII and DMNV neurons adopt both GABAergic and glycinergic synaptic inhibitions, they 
should express both types of receptors. To test this, we performed single-cell PCR analysis in 
individual XII and DMNV cells after electrophysiological recording. From the control group, 
both GABAAR- γ2 and GlyR- β transcripts were detected in XII (8 of 14) and DMNV (11 of 18) 
neurons (Figure 6A & C). In the other cells, we had either smear band (likely caused by RNA 
degradation) or GFAP detection (glia contamination), both of which were rejected from data 
analysis. We did not find a single band of either GABAAR- γ2 or GlyR- β transcripts in any XII 
or DMNV cells.  
In XII neurons, the optical density of GABAAR- γ2 vs GlyR- β was 1.00 vs 1.10 (0.96 ± 
0.19, n=8 vs 1.08 ± 0.15, n=8; P=0.18) (Figure 5.6B1). In DMNV cells, the optical density of 
GABAAR- γ2 vs GlyR- β = 1.00 vs 1.03 (0.93 ± 0.14, n=11 vs 0.96 ± 0.14, n=11; P=0.73) 
(Figure 5.6D1). These results together with our electrophysiological data indicate that 
GABAergic and glycinergic inhibitions are shared by the XII and DMNV neurons in roughly 
equal proportions.  
5.4.5 Miniature IPSCs in mice with Mecp2-disruption  
Previous studies indicate that several group of brainstem neurons are overly excited in animal 




inadequate synaptic inhibition by GABA, glycine, or both. Therefore, we studied mIPSCs in XII 
and DMNV neurons in brain slices obtained from male R168X mice. The baseline mIPSCs 
(including GABAAergic and glycinergic mIPSCs) were lower in these neurons than in those 
from the control mice without Mecp2 disruption. In XII neurons, the average baseline amplitude 
and frequency of mIPSCs were 11.6 ± 1.2 pA and 2.9 ± 0.7 Hz, respectively (n=15, Table 5.4), 
equivalent to 65.0% and 63.9% reductions compared to neurons from control mice. In DMNV 
neurons, the average baseline amplitude and frequency of mIPSCs were 22.0 ± 2.1 pA and 3.1 ± 
0.4 Hz, respectively (n=18; Table 5.4), reduced by 37.1% and 52.3% compared to neurons from 
control mice. 
With 10 µM Bccl exposure first followed by 1 µM Stcn, the mIPSC amplitude of XII 
neurons was inhibited by 29.2 ± 3.2% and 68.9 ± 3.7% (Bccl: 4.0±0.9pA, Stcn: 8.4±0.9pA, n=9), 
while the frequency was suppressed by 32.0 ± 6.4% and 64.1 ± 5.9%, respectively (Bccl: 
1.3±0.3Hz, Stcn: 2.7±0.7Hz, n=9) (Figure 5.4B1 & C; Table 5.4). In DMNV neurons, the mIPSC 
amplitude was inhibited by 30.9 ± 4.5% and 65.5 ± 4.5% (Bccl: 6.9±1.1pA, Stcn: 14.7±2.6pA, 
n=8), the frequency was reduced by 27.5 ± 1.6% and 50.5 ± 1.5%, respectively (Bccl: 
1.5±0.6Hz, Stcn: 1.9±0.4Hz, n=8) (Figure 5.5B1 & C; Table 5.4). 
With 1 µM Stcn first followed by 10 µM Bccl, the mIPSC amplitude of XII neurons was 
reduced by 69.6 ± 3.9% and 27.4 ± 4.8% (Stcn: 7.2±1.4pA, Bccl: 2.6±0.5pA, n=6), the 
frequency was suppressed by 72.1 ± 5.6% and 25.5 ± 6.0%, respectively (Stcn: 0.8±0.2Hz, Bccl: 
0.3±0.1Hz, n=6) (Figure 5.4B2 & D; Table 5.4). In DMNV neurons, the mIPSC amplitude was 
inhibited by 67.4 ± 4.2% and 30.3 ± 4.0% (Stcn: 15.3±2.9pA, Bccl: 5.9±0.7pA, n=8), the 
frequency was reduced by 65.0 ± 10.8% and 29.9 ± 8.6%, respectively (Stcn: 1.9±0.5Hz, Bccl: 




Compared to control neurons without Mecp2 disruption, the GABAAR-γ2 and GlyR-β 
mRNA levels in both XII & DMNV were lowered in R168X mice (Figure 5.6A & C). The 
proportion of these two receptor subunits was shifted towards glycine dominancy. In XII 
neurons, the optical density of GABAAR-γ2 vs GlyR-β was 1.00 vs 1.97 (0.17 ± 0.04 vs. 0.32 ± 
0.05, n=24; P=0.006) (Figure 5.6A & B2). In DMNV cells, the optical density of GABAAR-γ2 vs 
GlyR-β = 1.00 vs 3.37 (0.22 ± 0.05 vs. 0.73 ± 0.11, n=24; P=0.0003) (Figure 5.6A & D2).  
5.5 Discussion 
GABA and glycine are the most important inhibitory neurotransmitters in the 
developmentally mature mammalian CNS (Ito 2016). In the spinal cord glycine plays a 
prominent role, while GABA is believed to be the chief player in all other areas of the CNS 
(Scain, Le Corronc et al. 2010, Ito 2016). Previous studies have shown that GABA and glycine 
neurotransmitters are co-localized in interneurons in the cerebellar cortex (Crook, Hendrickson et 
al. 2006, Simat, Parpan et al. 2007) and retina (Koontz, Hendrickson et al. 1993). Co-expression 
of GABAA and glycine receptor subunits have also been found in motor neurons in the XII and 
spinal cord (Carlton and Hayes 1990, Christenson, Shupliakov et al. 1993, Ornung, Shupliakov 
et al. 1996, Tatetsu, Kim et al. 2012, Waldvogel, Biggins et al. 2019), and GABA / glycine are 
known to be essential during neuronal development and regeneration, although their functional 
consequences in regulating medullary neurons are still not clear, especially in RTT. Our 
observation in the present study strongly suggests that in the medulla oblongata GABA and 
glycine seem to play equally important roles in the inhibitory neurotransmission, and medullary 
neurons seem to rely more on glycine signaling in the mouse model of RTT.  
Our first evidence was from optogenetic studies in GAD-ChR transgenic mice by 




linked to eGFP in the open reading frame, its expression was identified with green fluorescence 
(Jin, Cui et al. 2013, Zhong, Cui et al. 2015). Functional studies confirmed the expression of 
ChR based on opto activation of inward cationic currents in voltage clamp and opto 
depolarization in current clamp in these eGFP-positive neurons. In eGFP-negative XII and 
DMNV cells opto activation of GAD-ChR neurons produces a clear inhibitory post-synaptic 
potential that has Cl- reversal potential and disappears in the presence of TTX, indicating that 
these XII and DMNV neurons are post-synaptic cells. This inhibitory neurotransmission was 
sensitive to GABAA receptor antagonist Bccl and glycine receptor antagonist Stcn. It can be 
suppressed but cannot be totally blocked by either alone. Only can a joint application of both 
Bccl and Stcn completely eliminate the opto IPSPs. With sequential applications of these 
blockers, we have found that amplitudes of the GABAergic and glycinergic IPSPs are roughly 
equal, which were observed in both XII cells and DMNV neurons. This indicates that opto 
stimulation triggers a release of GABA and glycine from the pre-synaptic GAD expressing 
neurons.  
We have obtained evidence for the inhibitory synaptic transmission via the measurement of 
mIPSCs with whole cell voltage clamp. This approach allows us to observe spontaneously 
occurring synaptic currents in a more natural condition without opto-stimulation. The Cl--
mediated inhibitory post-synaptic current was measured after elimination of glutamatergic 
currents, K+ currents and neuronal firing activity (Zhong, Cui et al. 2015). Clear mIPSCs have 
been found from XII / DMNV neurons, which can only partly be inhibited by the application of 
Bccl or Stcn alone. With a joint application of Bccl / Stcn, the mIPSCs are completely abolished, 
consistent with our observation with opto stimulation. By quantitative analyzed the data, we have 




findings suggest that XII /DMNV neurons receive both GABA and glycine from presynaptic 
neurons, which are released spontaneously or as a result of firing activity. When we applied the 
Bccl, Stcn or both, we found that the mIPSC frequency was also reduced, which is likely due to 
the suppression of the mIPSCs, leading to failure of detection of modest mIPSC events.  
Supporting the joint contribution of inhibitory synaptic transmission is another evidence from 
single cell PCR. We picked up a GABAA receptor subunit and a glycine receptor subunit in our 
single cell RT-PCR study, which have been previously demonstrated to be reliable markers for 
GABA and glycine receptor expressions (Haverkamp, Muller et al. 2004, Grudzinska, Schemm 
et al. 2005, Betz and Laube 2006). Our results from control mice have shown that XII and 
DMNV neurons have mRNA expressions of both GABAA receptor γ2 subunit and glycine 
receptor β subunit. The transcription levels do not show any significant difference between 
GABAARγ2 and GlyRβ in the XII or DMNV cells, results that are consistent with our 
electrophysiological findings described above.  
Previous studies have shown that in RTT mice with Mecp2 disruption, the GABA-mediated 
inhibitory signal is defective, attributable to the development of RTT-like breathing dysfunction 
(Chao, Chen et al. 2010, Lozovaya, Nardou et al. 2019). In contrast, how glycinergic inhibitory 
signal is affected in RTT models is poorly studied. A previous study showed that no genomic 
disturbances were found in glycine receptor α2 subunit located on the chromosome Xp22.2 
where there are several common mutations in RTT patients (Cummings, Dahle et al. 1998). 
Other studies indicated that the glycine receptor α3 subunit and glycine transporter 2 may be 
involved in the breathing abnormalities in RTT models (Hulsmann, Mesuret et al. 2016, Mesuret, 
Dannenberg et al. 2018). If medullary neurons adopt both GABAergic and glycinergic synaptic 




understood in the RTT mice. Indeed, our whole cell voltage clamp study has shown that the 
amplitude and frequency of mIPSCs in XII and DMNV neurons of the R168X mutation mice are 
significantly lower than those from control mice. In XII neurons, GABAAergic and glycinergic 
mIPSC amplitudes are lowered by ~80% and ~50% when comparing to their counterparts in 
control mice. In DMNV neurons, GABAAergic and glycinergic mIPSC amplitudes are lowered 
by ~62% and ~15% when comparing to control neurons. The proportions of the GABAAergic to 
glycinergic mIPSCs (amplitudes) shift from about 1:1 in control to 1:2 in R168X in both types of 
neurons. Thus, both GABA- and glycine-induced mIPSCs were significantly reduced in 
Mecp2R168X mice. Compared to GABAergic mIPSCs, the deficiency in glycinergic mIPSCs 
appears less severe, which may allow glycine to contribute more to the remaining inhibitory 
neuronal communication in XII & DMNV neurons. Our data suggest that the deficiency of 
GABAergic and glycinergic mIPSCs is more severe in XII neurons than in DMNV cells. This 
might be due to the functional differences between XII and DMNV neurons as the XII neurons 
are somatic motor neurons, whereas the DMNV neurons are visceral motor neurons. Functional 
maintenance of these motor outputs may rely on one of the neurotransmitters more than the 
other.  
We believe that the demonstration of brainstem neuronal adoption of dual inhibitory synaptic 
transmission is significant, which not only is a novel finding, but also reveals a potentially 
important mechanism. The brainstem controls several vital functions like respiratory control and 
cardiovascular control. Thus, additional conservational strategies may be necessary for survival. 
In comparison to GABAergic synaptic transmission (Wang, Johnston et al. 2005, Chao, Chen et 
al. 2010), glycinergic signals seem to be less affected in two types of medullary neurons. 




systems is still not fully understood, the better reserved glycinergic signals might serve to 
compensate, at a certain degree, the loss of GABA signaling. Therapeutically, the reserved 
glycinergic signals also could be targeted by promoting the pre-synaptic glycine release, 
increasing synaptic glycine levels by manipulating re-uptake, or enhancing the function of 
glycine receptors. These may improve the inhibitory synaptic inputs to medullary neurons 
alleviating RTT-like symptoms.  








 A. Schematics of sagittal section of the mouse brainstem containing the XII and the DMNV. 
B. In a coronal section at the obex level in the medulla oblongata, the XII and DMNV are easily 
identified (scale bar: 800μm). C. Schematics of opto-stimulation and whole-cell recording from 
GAD-ChR neurons. D. In another coronal section obtained from the medulla of GAD-ChR 
transgenic mice, eGFP positive neurons (D2) are located ventrolateral to hypoglossal area (D1). 
Scale bar: 200μm. E. In voltage clamp recording of GAD-expressing neurons, a clear inward 
photo current was evoked by 10ms (E1) and 50ms (E2) with opto-stimulation. F. In another eGFP 
positive cell, the photo current reversed its polarity with more depolarization (F1). The I-V 
relationship shows the reversal potential of the photo current at 0mV (F2). 
  




A. Schematics of whole cell recordings from XII and DMNV neurons with opto-stimulation. 
B1. The opto-stimulation produced hyperpolarization in a XII neuron without current injection. 
The hyperpolarization became smaller and smaller with hyperpolarizing current injections, and 
reversed its polarity with strong hyperpolarizing currents, which is better viewed when the traces 
are deliberately separated in B2. B3. When its amplitude is plotted against membrane potentials 
created by current injections, a reversal potential at near -60mV is seen, indicating that it is IPSP. 
 




In a DMNV neuron, opto-stimulation produced IPSP and inhibition of spontaneous firing 











Whole-cell current clamp was performed before and after blockade of GABA- receptor with 
10 µM Bccl and glycine receptor with 1 µM Stcn. A. in XII neurons, opto-stimulation produced 
IPSPs in the baseline. A1. The opto IPSP was diminished in the presence of Bccl, and totally 
abolished after exposures to both Bccl and Stcn. A2. In another XII cell, the IPSP was also 
partially blocked by Stcn and completely eliminated with Stcn and Bccl. B. Similar effects were 
observed in DMNV cells with the same sequences of application of these GABAA and glycine 
receptor blockers but neither alone. C, D. Quantitative analysis of the IPSP suppressions by Stcn 
and Bccl indicates that with application of Bccl first, the opto IPSP was significantly inhibited by 
5.4±1.1mV (P=0.0008, n=9) in XII neurons, and by 5.8±1.1mV (P=0.0006, n=9) in DMNV 
cells; then with Bccl plus Stcn, the opto IPSP was decreased by 5.2±1.1mV (P=0.0015, n=9) in 
XII and by 4.9±0.8mV (P=0.0003, n=9) in DMNV (C). With Stcn first, the opto IPSP was 
significantly inhibited by 7.6±1.3mV (P=0.0007, n=8) in XII and by 6.2±0.9mV (P=0.0003, 
n=11) in DMNV; then with Stcn / Bccl, the opto IPSP was totally eliminated by 5.2±0.8mV 
(P=0.0004, n=8) in XII and by 6.1±1.0mV (P=0.0004, n=11) in DMNV (D) (**, P<0.01; ***, 
P<0.001. Student’s t-Test). 
 
  
Figure 5.3 Involvement of both GABAergic and glycinergic synaptic inhibitions in XII and 










A1. The mIPSCs were studied in a XII neuron from a control mouse with sequential 
applications of Bccl (10 µM) and then Bccl (10 µM) / Stcn (1 µM). A2. In another XII cell from 
a control mouse, the blocker exposure sequence was switched to Stcn (1 µM) first and then Bccl 
(10 µM) / Stcn (1 µM). The IPSCs were completely eliminated by both blockers but not a single 
blocker alone. B. Similar experiments were done in XII neurons from mice with the R168X 
mutation. Under the same condition and blocker exposure sequence, suppressions of the mIPSCs 
were seen as in the control group of neurons, although the mIPSC amplitude and frequency were 
lower. C. Treatment with Bccl first significantly decreased the mIPSC amplitude by 18.8±1.6pA 
(P=0.0007, n=9) and frequency by 7.7±1.4Hz (P=0.025, n=9) in the control group. Such 
treatment reduced the amplitude by 4.0±0.9pA (P=0.0001, n=9) and frequency by 1.3±0.3Hz 
(P=0.025, n=9) in R168X group. With Bccl / Stcn, the mIPSC amplitude was suppressed by 
15.5±1.5pA (P=0.0002, n=9) and 8.4±0.9pA (P=0.0002, n=9) in the control and R168X groups, 
respectively, the frequency by 5.3±0.5Hz (P=0.0001, n=9) and 2.7±0.7Hz (P=0.0001, n=9), 
respectively. D. With Stcn first, the mIPSC amplitude was significantly decreased by 
16.0±1.8pA (P=0.0002, n=15), and the frequency by 2.3±0.5Hz (P=0.0002, n=15) in the control 
group. The same exposures reduced the amplitude by 7.2±1.4pA (P=0.0001, n=6) & frequency 
by 0.8±0.2Hz (P=0.0002, n=6) in R168X group. Similarly, joint application of Stcn / Bccl 
inhibited the mIPSC amplitude by 15.0±1.8pA (P=0.0002, n=15) and2.6±0.5pA (P=0.0002, 
n=6), and the frequency by 2.6±0.6Hz (P=0.0003, n=15) and 0.3±0.1Hz (P=0.021, n=6) in the 
Figure 5.4 Bicuculline and strychnine sensitivities of miniature IPSCs (mIPSCs) of XII 




control and R168X groups, respectively. (*, P<0.05; ***, P<0.001. Fisher’s LSD post hoc). For 
the amplitude of mIPSCs, the main effect of genotype (F = 79.5, df = 1, P = 0.0001), treatment 
(F = 83.2, df = 3, P = 0.0005) and interactions of genotype × treatment (F = 19.2, df = 3, P = 
0.0006) were significant (###, p < 0.001; Two-way ANOVA). As the frequency of mIPSCs, the 
main effect of genotype (F = 16.2, df = 1, P = 0.0001), treatment (F = 21.0, df = 3, P = 0.0008) 
and interactions of genotype × treatment (F = 4.3, df = 3, P = 0.007) were significant (##, p < 
0.01; Two-way ANOVA). E & F. Proportion of GABAA– and glycine-induced IPSC shifted 









A, B. The mIPSCs were studied in DMNV neurons under the same condition and the same 
blocker exposure sequence as shown for XII neurons in Figure 4, with similar results obtained. 
C. Treatment with Bccl first significantly decreased the mIPSC amplitude by 18.4±2.7pA 
(P=0.0003, n=9) and frequency by 3.7±0.7Hz (P=0.0009, n=9) in control group. It reduced the 
amplitude by 6.9±1.1pA (P=0.0003, n=8) and frequency by 1.5±0.6Hz (P=0.0008, n=8) in 
R168X group. With Bccl / Stcn, the mIPSC amplitude was decreased by 18.9±2.8pA (P=0.0006, 
n=9) and14.7±2.6pA (P=0.0006, n=8), and the frequency by 2.3±0.5Hz (P=0.001, n=9) and 
1.9±0.4Hz (P=0.001, n=8) in the control and R168X groups, respectively. D. Stcn first 
significantly decreased the mIPSC amplitude by 16.5±2.4pA (P=0.0007, n=9) and 15.3±2.9pA 
(P=0.0006, n=8), and the frequency by 3.6±0.7Hz (P=0.0002, n=9) and 1.9±0.5Hz (P=0.0003, 
n=8) in the control and R168X groups, respectively. Joint Stcn / Bccl totally inhibited the mIPSC 
amplitude by 15.0±2.3pA (P=0.0005, n=9) and 5.9±0.7pA (P=0.0006, n=8), and the frequency 
by 4.0±0.8Hz (P=0.001, n=9) and 0.7±0.2Hz (P=0.001, n=8) in the control and R168X groups, 
respectively. (**, P<0.01; ***, P<0.001. Fisher’s LSD post hoc). For the amplitude of IPSCs, the 
main effect of genotype (F = 12.9, df = 1, P = 0.001), treatment (F = 63.6, df = 3, P = 0.0001) 
and interactions of genotype × treatment (F = 3.3, df = 3, P = 0.024) were significant (#, p < 
0.05; Two-way ANOVA). As the frequency of IPSCs, the main effect of genotype (F = 12.1, df 
= 1, P = 0.001), treatment (F = 27.2, df = 3, P = 0.0009) and interactions of genotype × treatment 
(F = 4.8, df = 3, P = 0.004) were significant (##, p < 0.01; Two-way ANOVA). E & F. 
Proportion of GABAA– and glycine-induced IPSC shifted from 47.5±1.6% vs. 50.4±1.6% 
(control) to 30.6±2.9% vs. 66.5±2.9% (R168X). 
Figure 5.5 Bicuculline and strychnine sensitivities of miniature IPSCs (mIPSCs) of DMNV 




A. in XII neurons, the transcript levels of GABAA receptor γ2 subunit (GABAAR-γ2) / glycine 
receptor β subunit (GlyR-β) are clearly seen, which are also much stronger than those from XII 
neurons Mecp2 disruptions. In comparison of normalized transcript levels, these two receptor 
subunits had roughly equal photo-intensity in these two bands (GABAAR-γ2: 0.96±0.19, n=8; 
 
Figure 5.6 Single cell RT-PCR analysis of GABAA and glycine receptor transcripts in XII & 




GlyR-β: 1.08±0.15, n=8; P=0.18) (B1), while GlyR-β photo intensity was much stronger than 
GABAaR-γ2 in XII neurons with Mecp2 disruptions (GABAAR-γ2: 0.17±0.04, n=24; GlyR-β: 
0.32±0.05, n=24; P=0.006) (B2). C, D. Similar transcript expression patterns were seen in 
DMNV (Control: GABAAR-γ2, 0.93±0.14, n=11; GlyR-β, 0.96±0.14, n=11; P=0.73. R168X: 
GABAAR-γ2, 0.22±0.05, n=24; GlyR-β, 0.73±0.11, n=24; P=0.0003.) (**, P<0.01; ***, 



























XII 10.85 ± 1.73 5.45 ± 1.15  0.24 ± 0.06 7.66 ± 1.35 9 
DMNV 11.17 ± 1.74 5.35 ± 0.91  0.44 ± 0.11 7.77 ± 1.37 9 
XII 13.45 ± 2.15  5.82 ± 0.94 0.64 ± 0.12 6.47 ± 1.33 8 




















Target gene Primer sequence Accession No. 
GABAAR-γ2 FW TGACAACAAACTTCGACCTGAC 
NM 177408 
GABAAR-γ2 RV ATTGCTATTCAACCGGAGAACTT 
GlyR-β FW GACGCTTGTGCTAAAGAAAAGTC 
NM 010298 
GlyR-β RV CCAGCAGCCTGTTCAAGATATTG 
β-actin FW CACAGTGCTGTCTGGTGGTA 
NC 000071.6 
β-actin RV AGGGTATAAAACGCAGCTCAG 
Gfap FW CCCTGGCTCGTGTGGATTT 
NM 001131020 


































































































































































































































































































































































































































































































Table 5.4 mIPSC amplitude (Amp., pA) and frequency (Freq., Hz) from R168X 















































6 RESULT 2: CENTRAL EXCITATORY NEURONAL CONTROL OF CRD 
 
Published as “Hao Xing, Christopher M Johnson, Chun Jiang. Morphine-induced respiratory 
depression: behavioral, phrenic and brainstem respiratory neuronal evidence. PCT App. No. 
US/2020/033360. November 26, 2020.” 
A manuscript is submitted for publication 
Authors: Hao Xing, Ningren Cui, Hongmin Yao, Christopher M. Johnson, Chun Jiang. 
Cloperastine reduces morphine-induced respiratory depression in rats: Potential mechanisms for 
GIRK channel inhibition in locus coeruleus neurons. J Cell Physiol. Submitted.  
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6.2 Abstract 
Respiratory depression is the main cause of death in opioid drug misusage. Currently the 
only available therapeutic is naloxone drugs that also block certain desired opioid effects. Here 
we show evidence for alleviating the respiratory depression with the antitussive CPS. Studies 
were performed in conscious rats in vivo and in brains slices in vitro. In plethysmography, CPS 
(30 mg/kg, s.c.) alleviated, but not eliminated, morphine-induced breathing depression. CPS oral 
treatment (30 mg/kg/day, 7-day) shifted LD50 of morphine (i.p.) from 106 mg/kg to 130 mg/kg. 
Morphine increased K+ current in GIRK2/MOR double transfected HEK cells, which was 
reversed by 5μM CPS. Morphine hyperpolarized locus coeruleus neurons, raised their input 
resistance and decreased firing activity, all of which can be reversed by CPS. Removal of 
neuronal firing activity with 0.5 μM TTX reduced the cellular responses of both morphine & 




by CPS, suggesting that both pre- and postsynaptic mechanisms are involved. The presynaptic 
cells are likely to be AMPA-targeted glutamatergic neurons as CNQX had a similar effect to 
TTX. The presynaptic mechanisms involved GIRK channels in synaptic terminals, as CPS 
increased mEPSCs amplitude & frequency in LC cells to the same degree as the metabotropic 
glutamate receptor blocker LY341495. CPS alleviates morphine-induced breathing depression 
and improves morphine LD50. In LC neurons, CPS seems to counteract morphine via blocking 
GIRK channels 1) in LC cells, 2) in presynaptic glutamatergic neurons, and 3) in glutamatergic 
synaptic terminals. Because these GIRK channels are the major downstream target of MOR, it is 
possible that CPS interacts with morphine by blocking GIRK signaling. 
6.3 Introduction 
A major adverse effect of the chronic use of opioid drugs is progressive respiratory 
depression causing a loss of a large number of lives worldwide (Burke 2016, Jalal, Buchanich et 
al. 2018). The opioid-induced CRD involves the brainstem respiratory neuronal networks and 
CO2 chemoreceptors. Targeting on them, several CRD therapeutics have been developed, 
including respiratory stimulants (Dahan, van der Schrier et al. 2018) and opioid receptor 
antagonists (Yousefifard, Vazirizadeh-Mahabadi et al. 2020) . Dahan et al. have recently 
analyzed most respiratory stimulants in OIRD treatments, including doxapram, GAL021, 
ampakines, 5-HT receptor agonists, D1-dopamine receptor agonists, phospodiesterase-4 
inhibitors, the endogenous peptide glycyl-glutamine, and thyrotropin-releasing hormone. The 
authors conclude that none of these experimental drugs are adequate for therapeutic use in OIRD 
(Dahan, van der Schrier et al. 2018). Thus, naloxone types of µ-opioid receptor (MOR) 




the MOR antagonists as preventive drugs does not seem practical, as they tend to antagonize 
therapeutic objectives including nociception relieves.  
The GIRK channel, which is a downstream effector of MOR, is known to be involved in the 
mechanism of OIRD (Luscher and Slesinger 2010, Liang, Yong et al. 2018). Functional GIRK 
channels in the CNS mainly consist of 2 pairs of heteromeric GIRK1, GIRK2 and GIRK3, or 
homomeric GIRK2 (Kofuji, Davidson et al. 1995, Lesage, Guillemare et al. 1995, Liao, Jan et al. 
1996, Luscher, Jan et al. 1997, Signorini, Liao et al. 1997, Jelacic, Kennedy et al. 2000, 
Torrecilla, Marker et al. 2002). These GIRK channels are activated by a number of 
neurotransmitters, such as GABA through GABAB receptors (Takigawa and Alzheimer 1999, 
Wetherington and Lambert 2002), metabotropic glutamate receptors (Saugstad, Segerson et al. 
1996, Knoflach and Kemp 1998), serotonin through 5-HT1A receptors, adenosine through A1 
receptors, acetylcholine through M2 receptors, opioids through µ,  and  receptors, and 
dopamine through D2 receptors (Mansour, Khachaturian et al. 1987, North, Williams et al. 1987, 
Einhorn and Oxford 1993, Jeong, Han et al. 2001, Wetherington and Lambert 2002, Ivanina, 
Varon et al. 2004). The activation of these K+ channels leads to efflux of K+, hyperpolarization 
of neurons and a reduction in their excitability, while activation of the GIRK channels in 
presynaptic terminals inhibits neurotransmitter release from the synaptic terminals.  
GIRK channels are activated by several opioid receptor agonists (Mansour, Khachaturian et 
al. 1987, North, Williams et al. 1987). Treatment of the locus coeruleus neurons with [Met]5-
enkephalin induces activation of whole-cell K+ currents and hyperpolarization (Pepper and 
Henderson 1980), which are reduced by 40% in GIRK2 knockout mice and by 80% in 
GIRK2/GIRK3 double knock-out mice (Torrecilla, Marker et al. 2002). MOR agonists inhibit 




channels (Williams, Christie et al. 2001, Stotzner, Spahn et al. 2018). GIRK2 and GIRK3 are 
required for the morphine withdrawal effects, as genetic disruption of these channels in mice 
markedly attenuates the morphine withdrawal syndrome without affecting morphine analgesia 
(Cruz, Berton et al. 2008). Pre-treatment with the GIRK channel blocker Tertiapin-Q dose-
dependently reverses the fentanyl-induced changes in respiratory rate and inspiratory time 
(Liang, Yong et al. 2018). MOR agonist suppresses rhythmic breathing in wild-type but not in 
GIRK2-knockout mice (Montandon, Ren et al. 2016). The depression in breathing activity after 
MOR agonist can be reversed by GIRK channel blocker (Montandon, Ren et al. 2016). The 
pontine group of respiratory neurons in the KF is hyperpolarized by MOR agonist accompanied 
by apneusis, effects that can be blocked by GIRK channel inhibitors (Levitt, Abdala et al. 2015).  
Theoretically, GIRK channel inhibitors may have widespread effects by acting on multiple 
brain areas where GIRK channels are expressed. However, some GIRK channel inhibitors appear 
relatively selective for the brainstem respiratory neuronal networks. By taking such an 
advantage, some drugs have been developed as central antitussives, such as CPS. CPS is an over-
the-counter antitussive approved in several Asian and European countries with excellent safety 
records (Catania and Cuzzocrea 2011, Soeda, Fujieda et al. 2016). The primary function of CPS 
in the brainstem is to block GIRK channels leading to inhibitions of the respiratory neuronal 
networks, although it has σ receptor agonistic and antihistaminic properties as well (Catania and 
Cuzzocrea 2011, Soeda, Fujieda et al. 2016). . To test the hypothesis that CPS alleviates 
morphine-induced respiratory depression, we performed these studies. Meanwhile we 





6.4.1 CPS alleviated morphine-induced respiratory depression  
Breathing activity was measured in whole-body plethysmography. During a 20-min 
recording the baseline breathing amplitude (tidal volume) averaged 0.35±0.08 ml·100g-1 (N=37 
rats), and the breathing frequency was 2.0±0.1 Hz (N=37 rats). The calculated minute ventilation 
(minV = Ti × f) was 41.66±2.53 ml·min-1·100g-1 (N=37 rats). 
Twenty minutes after CPS injection (30 mg/kg, s.c.), the tidal volume, breathing frequency 
and minute ventilation were 0.38±0.02 ml·100g-1, 1.8±0.0 Hz and 40.92±2.48 ml·min-1·100g-1 
(N=5 rats), respectively. No significant difference was found statistically (Fig 6.1, Table 6.1).  
Drastic changes in these respiratory parameters occurred after morphine injection (10 mg/kg, 
i.p.). Breathing became slow and irregular with frequent apneas. The effects reached the 
maximum level around 20min after morphine injection and remained at the level for another 
~100min. At the plateau level, the tidal volume (0.23±0.08 ml·100g-1, p=0.000134, N=12) 
breathing frequency (0.5±0.1Hz, p=0.000279, N=12) and minute ventilation (7.36±1.26 ml·min-
1·100g-1, p=0.000615, N=12) were all significantly depressed in comparison to the baseline 
levels. By the time of 240 min after morphine injection, the tidal volume (0.31±0.02 ml·100g-1, 
p=0.981, N=12), breathing frequency (1.9±0.1Hz, p=0.490, N=12) and minute ventilation 
(35.29±2.80 ml·min-1·100g-1, p=0.642, N=12) returned to prior morphine levels showing no 
significant differences from the baseline levels of breathing. 
In the time range between 20~60 min after morphine injection, the effects of morphine were 
rapidly and partially reversed with a dose of CPS injection (Fig 6.1, Table 6.1). A pretreatment 
with CPS also diminished the effects of following morphine injection. Both were significantly 




6.4.2 CPS improved rat survival after morphine overdose  
If CPS treatment alleviates morphine-induced respiration depression, such a treatment should 
improve survival. To test the hypothesis, we studied the death rate at various doses of morphine 
in two groups of rats. One group was treated with CPS in the drinking water (30 mg/kg/day for 7 
continuous days), and the other was given normal drinking water for 7 continuous days. On the 
8th day, each rat received a single dose of morphine injection (i.p.). None of these rats had 
previous exposure to any other agents. 
The survival rate was calculated as number of survival / total (survival + death), the survival 
histogram was drawn as morphine dose vs. survival rate for each group. We also tried to describe 
their relationship with Hill equation, the LD50 of morphine treatment for control group is 106 
mg/kg (i.p.). For CPS group (30mg/kg/day, 7-days), LD50 of morphine located around 130 
mg/kg (i.p.). The CPS oral administration significantly shifted the survival curve of morphine 
treatment rightward (χ2 (1, N=130) = 5.335, p = 0.0209, Mantel-Cox test. Fig 6.2, Table 6.2).  
6.4.3 CPS counteracted GIRK channel activation after morphine exposure  
The opioid-induced respiration depression is mainly mediated by the μ opioid receptor. 
Activation of these receptors leads to activation of the GIRK channels and hyperpolarization. In 
the CNS, these channels are made of heteromeric GIRK1-GIRK3 or homomeric GIRK2 (Corey, 
Krapivinsky et al. 1998). Thus, we co-transfected HEK cells with GIRK2 and μ opioid receptor. 
Whole-cell voltage clamp was performed in the HEK cells 2 days after transfection. The GIRK 
channels mediated K+ currents were seen in the transfected HEK cells, which showed inward 
rectification and were strongly inhibited by Ba2+ (100 μM). The current amplitude increased 




plateau of the morphine activated currents, CPS (5μM) reversed the currents to nearly the 
baseline level (Fig 6.3 A1, A2; Table 6.3).  
When applied before morphine, CPS suppressed the amplitude of baseline K+ current from 
215.2±24.1pA to 67.8±7.5pA. Under this condition, the same contraction of morphine (10 μM) 
produced only modest current activation from 67.8±7.5pA to 176.5±26.7pA (Fig 6.3 B1, B2; 
Table 6.3). Statistical analysis indicated that the morphine effects on GIRK2 current activation 
were significantly reduced by CPS applied either before or after morphine treatment.  
6.4.4 CPS diminished morphine-induced inhibition of LC neurons  
CPS is a central antitussive acting in the CNS, likely on the brainstem neuronal networks. 
Neurons in the LC are known to be a part of such neuronal networks, play an important role in 
breathing regulation, and form a major target of opioid drugs (Medrano, Santamarta et al. 2017). 
Hence, we chose the LC neurons for the study of potential CPS-morphine interaction.  
Consistent with previous reports (Torrecilla, Quillinan et al. 2008), exposure of LC neurons to 
morphine (5 μM) in the brain slice preparation produced strong hyperpolarization of the cells 
together with an increase in the input resistance and a decrease in spontaneous firing (Fig 6.4 A1, 
A2, A3, A4; Table 6.4).  
With the continuing presence of morphine, application of CPS (20 μM) to the perfusion 
solution led to fast reversal, though not complete, of the morphine effects (Fig 6.4 A1, A2, A3, 
A4; Table 6.4). A pretreatment of the LC neurons with CPS produced small but significant 
depolarization and increased firing rate, while cellular responses to following morphine 




6.4.5 Pre-/post synaptic mechanisms in regulating LC excitability  
To understand whether the CPS-morphine interaction occurs within the LC neurons or 
involves presynaptic cells. Experiments were performed in the presence of TTX (0.5 μM) to 
block synaptic transmissions. Under this condition, morphine hyperpolarized the LC cells to 
much smaller degree (Fig 6.5 A1, A2, A3; Table 6.4). Similarly, the input resistance was 
decreased from 562.0±15.5ΩM to 465.7±15.7ΩM, significantly less than without TTX (Fig 6.5 
A1, A2, A3; Table 6.4). In the presence of TTX, CPS produced smaller depolarization of the LC 
neurons and raised their input resistance to a less degree, which were seen before and after 
morphine exposure (Fig 6.5 B1, B2, B3; Table 6.4). These results suggest that although both CPS 
and morphine act on postsynaptic LC neurons, these cells are not the only target and presynaptic 
mechanisms are involved as well.  
The observations above indicate that CPS has excitatory effects on the LC neurons, while the 
morphine effects are inhibitory. If presynaptic mechanisms are involved, they should be 
mediated by excitatory neurons rather inhibitory neurons. This is due to the fact that dis-
inhibition requires firing of two inhibitory neurons and cannot take place in the presence of TTX. 
Therefore, we performed whole-cell current clamp with 20μM CNQX to block the AMPA 
receptor. Similar to the TTX experiments, the inhibitory effects of morphine and excitatory 
effects of CPS were both significantly diminished (Fig 6.6 A1, A2, A3, A4; Table 6.4). When 
compared to their levels after TTX treatment, there was no significant difference in LC neuronal 
response between TTX and CNQX treatments (Fig 6.6 A1, A2, A3, A4; Table 6.4), suggesting 
that presynaptic glutamatergic neurons are involved. 
In addition to the GIRK channels in soma and dendrites, CPS may act on GIRK channels in 




regulation of glutamate release mediated by the metabotropic glutamate receptors. Thus, we 
carried out voltage clamp measuring glutamatergic miniature EPSCs (mEPSCs) in the LC 
neurons. We found that CPS exposure raised the amplitude of the mEPSCs from 14.0±1.8pA to 
18.6±2.1pA, and increased mEPSCs frequency from 2.6±0.1Hz to 4.0±0.4Hz (Fig 6.7 A1, A2, 
A3; Table 6.5). The effects of CPS were likely to be mediated by the presynaptic metabotropic 
glutamate receptors, because LY341495, a selective blocker of these receptors, had similar 
effects, and because CPS had no additional effects on the mEPSCs after LY341495 treatment 
(Fig 6.7 B1, B2, B3; Table 6.5). 
6.5 Discussion 
GIRK channels are one of the two downstream targets of MOR, which is involved in the 
regulation of brainstem respiratory neurons (Williams, Christie et al. 2001, Stotzner, Spahn et al. 
2018). GIRK channels are a group of K+ channels whose activation relies on the direct 
interaction with the Gβγ subunit of G proteins. GIRK channels are expressed widely in most 
tissues and cells, where they participate in the regulation of various cellular activity. In the CNS, 
GIRK channels are activated by a number of neurotransmitters (Einhorn and Oxford 1993, 
Saugstad, Segerson et al. 1996, Knoflach and Kemp 1998, Takigawa and Alzheimer 1999, 
Jeong, Han et al. 2001, Wetherington and Lambert 2002, Ivanina, Varon et al. 2004). Opioids 
through µ, σ and κ receptors are also key mechanism to activate GIRK channels (Mansour, 
Khachaturian et al. 1987, North, Williams et al. 1987). The activation of these K+ channels leads 
to hyperpolarization of postsynaptic cells reducing their excitability, while activation of the 
GIRK channels in presynaptic terminals inhibits neurotransmitter release from the synaptic 
terminals. Treatment of the locus coeruleus neurons with MOR agonist induces activation of 




(Pepper and Henderson 1980, Torrecilla, Marker et al. 2002). MOR agonists inhibit neurons in 
the periaqueductal gray and the dorsal root ganglion through activation of GIRK channels.  
Inhibition of the GIRK channels has excitatory effects on neuronal firing activity and 
breathing (Levitt, Abdala et al. 2015, Liang, Yong et al. 2018). The respiratory depression 
induced by DAMGO, a peptide MOR agonist, can be reversed by the GIRK channel blocker 
Tertiapin-Q (Montandon, Ren et al. 2016). Tertiapin-Q is a synthesized bee venom peptide, and a 
useful tool for laboratory research. It blocks multiple types of K+ channels and needs to be 
applied by local injection in a brain area (Montandon, Ren et al. 2016). In contrast, CPS is an 
oral antitussive, and can pass through blood brain barrier. Thus, our finding in the current studies 
has apparently advanced the research for potential treatment and prevention of CRD.  
CPS blocks GIRK channels, while morphine activates them, by producing depolarization and 
hyperpolarization, respectively. Although these apparently opposite effects can take place in a 
cell, it is necessary to demonstrate whether CPS and morphine share some common cellular 
processes, and where the potential interaction occurs.  
If the CPS interacted with morphine in LC neurons by postsynaptic mechanism only, on the 
one hand, elimination of presynaptic input would not affect the levels of excitation and inhibition 
produced by CPS and morphine. If the interaction were solely presynaptic, on the other hand, 
both effects would be abolished after blockade of synaptic transmission. Testing the possibilities, 
we used TTX to block firing activity of all neurons. Under this condition, we have found that the 
effects of morphine and CPS on LC neurons cannot be maintained, neither eliminated. Instead, 
LC neurons show intermediate levels of inhibition and excitation by morphine and CPS, 
respectively. The remaining inhibitory effect of morphine can be totally blocked by CPS, a 




In addition to the reduction of morphine and CPS effects in the presence of TTX, our results 
show that CPS does not completely eliminate the morphine-induced LC neuronal inhibition 
when presynaptic inputs remain intact, which also supports the presence of presynaptic 
interaction. CPS could produce excitatory effects by inhibition of GIRK channels in presynaptic 
glutamatergic neurons, or by excitation of a pre-presynaptic inhibitory neuron that inhibits 
another presynaptic inhibitory neuron. This is known as disinhibition. Our results do not support 
such a mechanism, as firing activity required for disinhibition cannot be brought about in the 
presence of TTX. Consistent with such a scenario, we have found that blockade of AMPA 
receptors with CNQX has an identical effect as TTX. Thus, it is likely that the presynaptic 
interaction of CPS with morphine occurs in glutamatergic neurons. 
Besides these post- and presynaptic cellular mechanisms, CPS may also block GIRK in the 
presynaptic terminals. When applying a metabotropic glutamate receptor blocker LY341495, we 
have found that glutamatergic mEPSCs are augmented, indicating the presence of feedback 
regulation of glutamate release from the presynaptic terminals by the metabotropic glutamate 
receptors. A similar increase in the mEPSCs has been observed when we applied CPS. 
Therefore, these results suggest that CPS depolarizes LC neurons by blocking GIRK channels in 
1) soma and/or dendrites of LC cells, 2) presynaptic glutamatergic neurons, and 3) presynaptic 
glutamatergic terminals. 
It is worth noting that our currents studies are not providing evidence of cellular mechanisms 
of CPS-morphine interaction. Our in vivo studies have shown that CPS treatment significantly 
shifts the LD50 of morphine (i.p.) rightward. This as well as the fact that CPS is an over-the-
counter antitussive in several Asian and European countries suggests that further studies in 




Although our findings are encouraging, several questions remain open: It is known that CPS 
interacts with not only GIRK channels, but also σ receptors and histamine receptors, and these 
interactions may have additional effects either favorable or unfavorable in the regulation of 
brainstem neuron activity during CRD. In our previous studies CPS (30 mg/kg. i.p.) was used 
without any detectable adverse side effects in mice. We found that with a higher concentration of 
CPS (≥30 mg/kg) injected intraperitoneally caused suspicious seizure in 2 of 7 rats after high 
dose morphine treatment (≥10mg/kg, i.p.), while none of the other 5 rats with CPS (30 mg/kg. 
i.p.) showed similar symptom. Because of this, no data of these 7 rats were used in current study. 
Subsequently, we tried subcutaneous application of the same dose of CPS (30 mg/kg). No rats 
showed any abnormalities. Clearly, further pharmacokinetic studies of CPS are needed to 
determine the difference of different methods of application as well as species difference 
between rats and mice. GIRK channels are expressed in various tissues and cells. As an 
antitussive medicine, CPS affects the activity of GIRK channel, works on the brainstem cough 
center to suppress cough. But if brainstem the only or main target of CPS, and how other brain 
areas are affected by CPS is unknown. Furthermore, in vivo studies of phrenic nerve activity, and 
activity of neurons in pons & medullary respiratory groups are necessary with parallel 








Figure 6.1 Effects of morphine / CPS on whole-body breathing activity.  
A, Morphine injection before CPS. B, Cloperastine injection before morphine. C, Analyzed 
drugs effects. During a 20-min baseline recording the tidal volume was 0.35±0.08 ml·100g-1 
(N=37), the breathing frequency was 2.0±0.1 Hz (N=37), and the minute ventilation was 




0.38±0.02 ml·100g-1 (N=5), the breathing frequency was 1.8±0.0 Hz (N=5), and the minute 
ventilation was 40.92±2.48 ml·min-1·100g-1 (N=5). All the tidal volume (p=0.610), breathing 
frequency (p=0.827) and minute ventilation (p=0.653) of CPS treatment shown no significant 
difference with baseline breathing. As we only injected rat with morphine, 20min till 120min 
after morphing injection, the tidal volume (0.23±0.08 ml·100g-1, p=0.000134, N=12) breathing 
frequency (0.5±0.1 Hz, p=0.000279, N=12) and minute ventilation (7.36±1.26 ml·min-1·100g-1, 
p=0.000615, N=12) were all significantly depressed than baseline. By the time of 240 min after 
morphine injection, the tidal volume (0.31±0.02 ml·100g-1, p=0.981, N=12), breathing 
frequency (1.9±0.1 Hz, p=0.490, N=12) and minute ventilation (35.29±2.80 ml·min-1·100g-1, 
p=0.642, N=12) had no significant differences with baseline breathing. Based on the average 
data from 20~60 min time range, as we give CPS together with morphine, we found the tidal 
volume (0.28±0.03 ml·100g-1, N=11) was better than morphine maximum effect (p=0.0158), but 
still depressed than CPS treatment (p=0.00952); the breathing frequency (1.2±0.0 Hz, N=11) was 
better than morphine treatment (p=0.0294) but still depressed than CPS treatment (p=0.00432); 
the minute ventilation (20.24±0.76 ml·min-1·100g-1, N=11) was better than morphine treatment 
(p=0.0228) but depressed than CPS treatment (p=0.00259). There were statistically significant 
differences between group means as determined by one-way ANOVA: F (3, 91) = 95.50, p= 






Figure 6.2 CPS shifted the survival curve of morphine rightward.  
The survival percentage at difference morphine doses were: at morphine dose 48mg/kg, all 
rats from CPS and control groups were survived (N=7 rats per group); at morphine dose 
68mg/kg, CPS survival rate was 100.0% (N=7), control group survival rate was 85.7% (6 
survived, 1 died, N=7); at morphine dose 88mg/kg, CPS survival rate was 90.0% (9 survived, 1 
died, N=10), and control group survival rate was 70.0% (7 survived, 3 died, N=10); at reported 
morphine LD50 dose 108mg/kg, CPS survival rate was 80.0% (8 survived and 2 died, N=10), 
control group survival rate was 50.0% (5 survived and 5 died, N=10); at the morphine dose 
128mg/kg, CPS survival rate was 60.0% (6 survived and 4 died, N=10), and control group 
survival rate was 20.0% (2 survived and 8 died, N=10); at the morphine dose 140mg/kg, survival 
rate of CPS group was 42.9% (3 survived and 4 died, N=7), and control group survival rate was 
0% (7 died, N=7); at the morphine dose 150mg/kg, CPS survival rate was 14.3% (1 survived and 




170mg/kg, all tested rats from both groups were died (N=7 rats per group). The 30mg/kg/day, 7-
days CPS oral administration significantly shifted the survival curve of i.p. morphine treatment 





Figure 6.3 Effects of morphine/CPS on K+ current in GIRK2/MOR transfected HEK Cells.  
A, morphine treatment before CPS. B, CPS treatment before morphine. A1, B1, recording 
traces of K+ current with drug treatment. A2, B2, analyzed amplitude of GIRK2 current. When 
we gave morphine before CPS, the morphine treatment increased K+ current amplitude from 
208.8±24.1pA to 488.7±42.1pA, with a changing level of 279.8±33.8pA (p=0.00144); then we 
gave morphine together with CPS, the amplitude of K+ current reduced from 488.7±42.1pA to 
160.5±17.7pA, with a changing level of 328.2±44.6pA (p=0.00517, N=6). When we applied CPS 
before morphine, CPS reduced the amplitude of K+ current from 215.2±24.1pA to 67.8±7.5pA, 
with a changing level of 147.3±23.2pA (p=0.000418); then morphine & CPS were applied 
together, the amplitude of K+ current increased from 67.8±7.5pA to 176.5±26.7pA, with a 




differences between group means as determined by one-way ANOVA: F (3, 32) = 53.11, p= 







Figure 6.4 Morphine / CPS affected the firing activity of LC neuron.  
A1, B1, whole-cell current clamp recording traces of drug treatment. A2, A3, A4, B2, B3, B4, 
analyzed membrane properties. Morphine hyperpolarized LC membrane from -56.0±1.8mV to -
67.8±1.3mV, with a changing level of 11.8±1.4mV (p=0.000954); increased input resistance 




decreased firing frequency from 2.5±0.4Hz to 0 Hz, with a changing level of 2.5±0.4Hz 
(p=0.000276). Then we applied CPS with morphine, the membrane potential changed from -
67.8±1.3mV to -50.4±1.1mV, with a changing level of 17.4±1.1mV (p=0.000203); input 
resistance changed from 601.7±25.0ΩM to 778.6±40.1ΩM, with a changing level of 
176.8±32.3ΩM (p=0.000272); spontaneous firing frequency changed from 0Hz to 0.5±0.1Hz, 
with a changing level of 0.5±0.1Hz (p=0.00239, N=11). With CPS treatment before morphine: 
CPS depolarized LC neuron membrane potential from -55.0±2.2mV to -48.4±1.8mV, with a 
changing level of 6.6±1.6mV (p=0.00178); increased input resistance from 467.2±66.7ΩM to 
639.3±65.7ΩM, with a changing level of 172.2±31.6ΩM (p=0.000284); firing frequency was 
increased from 2.5±0.4Hz to 3.6±0.5Hz, with a changing level of 1.1±0.2Hz (p=0.00131). As we 
applied morphine+CPS after then, membrane potential was hyperpolarized from -48.4±1.8mV to 
-50.4±1.5mV, with a changing level of 3.3±0.5mV (p=0.0669); input resistance increased from 
639.3±65.7ΩM to 708.7±61.8ΩM, with a changing level of 69.4±28.3ΩM (p=0.0342); firing 
frequency decreased from 3.6±0.5Hz to 0.5±0.1Hz, with a changing level of 3.1±0.4Hz 
(p=0.000116, N=11). There were statistically significant differences between group means as 
determined by one-way ANOVA: F (3, 51) = 7.192, p= 0.000413. (*, p≤0.05; **, p≤0.01; ***, 





Figure 6.5 Effects of morphine / CPS on LC firing activities with TTX application.  
A1, B1, whole-cell current clamp recording traces of drug treatment. A2, A3, B2, B3, analyzed 
membrane properties. We applied the perfusion system with 0.5 μM TTX to block the neuronal 




membrane potential from -48.2±0.7mV to -53.1±0.7mV, with a changing level of 4.9±0.3mV 
(p=0.000101); input resistance decreased from 562.0±15.5ΩM to 465.7±15.7ΩM, with a 
changing level of 96.2±19.3ΩM (p=0.00158). Then we gave CPS together with morphine, the 
membrane potential depolarized from -53.1±0.7mV to -50.2±0.4mV, with a changing level of 
2.9±0.4mV (p=0.000687); input resistance increased from 465.7±15.7ΩM to 507.9±9.3ΩM, with 
a changing level of 42.2±10.0ΩM (p=0.00389, N=8). When treated with CPS before morphine: 
CPS depolarized membrane potential from -48.1±0.7mV to -46.0±0.6mV, with a changing level 
of 2.1±0.3mV (p=0.00114); input resistance was increased from 562.0±14.7ΩM to 
587.6±16.0ΩM, with a changing level of 25.6±5.9ΩM (p=0.0337). Then we gave CPS with 
morphine, the membrane potential changed from -46.0±0.6mV to -50.2±1.0mV, with a changing 
level of 4.2±0.6mV (p=0.00245); input resistance changed from 587.6±16.0ΩM to 
411.2±12.6ΩM, with a changing level of 176.4±14.0ΩM (p=0.000466). After that, we gave only 
morphine after this morphine+CPS to test the maximum morphine effect, the membrane 
potential was further hyperpolarized from 50.2±1.0mV to -51.9±0.8mV, with a changing level of 
1.7±0.4mV (p=0.00257); input resistance further decreased from 411.2±12.6ΩM to 
360.4±6.6ΩM, with a changing level of 50.8±11.9ΩM (p=0.00366, N=8). There were 
statistically significant differences between group means as determined by one-way ANOVA: F 
(3, 36) = 16.974, p= 0.000147. (*, p≤0.05; **, p≤0.01; ***, p≤0.001; Bonferroni’s post hoc test). 






Figure 6.6 Effects of morphine / CPS on LC membrane properties with CNQX 
administration.  
A1, B1, whole-cell current clamp recording traces of drug treatment. A2, A3, A4, B2, B3, B4, 
analyzed membrane properties. We gave 20μM CNQX in the perfusion solution to block the 
AMPA receptor. With morphine treatment before CPS: Morphine hyperpolarized membrane 
potential of LC cell from -48.4±0.5mV to -52.5±0.4mV, with a changing level of 4.2±0.4mV 
(p=0.000152); input resistance was reduced from 622.6±11.1ΩM to 258.6±18.1ΩM, with a 




2.0±0.2Hz to 0Hz, with a changing level of 2.0±0.2Hz (p=0.000766). Then we gave 
morphine+CPS after the morphine treatment, the membrane potential was depolarized from -
52.0±0.4mV to -46.4±0.6mV, with a changing level of 6.1±0.7mV (p=0.000275); input 
resistance was increased from 258.6±18.1ΩM to 543.8±15.6ΩM, with a changing level of 
285.2±25.8ΩM (p=0.000105); the firing frequency increased from 0Hz to 0.4±0.1Hz, with a 
changing level of 0.4±0.1Hz (p=0.0115, N=7). With the CPS treatment before morphine: The 
CPS depolarized membrane potential from -47.8±0.5mV to -44.9±0.2mV, with a changing level 
of 3.0±0.5mV (p=0.000668); input resistance increased from 633.1±21.9ΩM to 694.8±20.9ΩM, 
with a changing level of 61.6±9.2ΩM (p=0.00529); firing frequency increased from 1.8±0.2Hz 
to 2.0±0.2Hz, with a changing level of 0.3±0.0Hz (p=0.0387). Then we gave morphine+CPS 
after this CPS treatment, the membrane potential was hyperpolarized from -44.9±0.2mV to -
49.2±0.8mV, with a changing level of 4.3±0.8mV (p=0.00155); input resistance decreased from 
694.8±20.9ΩM to 578.7±21.7ΩM, with a changing level of 116.1±4.8ΩM (p=0.000329); firing 
frequency decreased from 2.0±0.2Hz to 0.4±0.1Hz, with a changing level of 1.6±0.2Hz 
(p=0.000396). We also gave only morphine treatment after this morphine+CPS treatment to test 
the maximum morphine effects, the membrane potential was further hyperpolarized from -
49.2±0.8mV to -52.0±0.6mV, with a changing level of 2.8±0.4mV (p=0.00216); input resistance 
even decreased from 578.7±21.7ΩM to 243.2±14.8ΩM, with a changing level of 335.5±12.4ΩM 
(p=0.000168); firing frequency decreased from 0.4±0.1Hz to 0Hz, with a changing level of 
0.4±0.1Hz (p=0.0116, N=7). There were statistically significant differences between group 
means as determined by one-way ANOVA: F (3, 21) = 128.421, p= 0.000184. (*, p≤0.05; **, 






Figure 6.7 CPS affected mEPSCs on LC via regulating presynaptic GIRK channels.  
A1, B1, whole-cell voltage clamp recording traces of drug treatment. A2, A3, B2, B3, analyzed 
mEPSCs amplitude and frequency. When we applied the recording slice with CPS, the mEPSCs 
amplitude was increased from 13.7±1.1pA to 18.5±1.3pA, with a changing level of 4.8±0.5pA 




of 1.1±0.2Hz (p=0.00290). Then we gave CPS+CNQX after the CPS treatment, we fine mEPSCs 
amplitude was reduced from 18.5±1.3pA to 0.5±0.1pA, with a changing level of 18.0±1.2pA 
(p=0.000143); and the mEPSCs frequency was reduced from 3.5±0.3Hz to 0.3±0.1Hz, with a 
changing level of 3.2±0.3Hz (p=0.000798, N=10) We also gave 20μM LY341495 before CPS 
treatment. LY341495 increased mEPSCs amplitude from 13.0±1.4pA to 19.6±2.0pA, with a 
changing level of 6.7±0.8pA (p=0.00203); the frequency increased from 2.9±0.2Hz to 
4.8±0.3Hz, with a changing level of 1.9±0.2Hz (p=0.000807). As we gave CPS after this 
LY341495 treatment, the mEPSCs amplitude slightly increased from 19.6±2.0pA to 21.3±1.5pA, 
with a changing level of 2.9±1.1pA (p=0.249); and the mEPSCs frequency increased from 
4.8±0.3Hz to 5.2±0.2Hz, with a changing level of 0.6±0.2Hz (p=0.0920). After the CPS 
treatment, we applied CNQX together with CPS, the mEPSCs amplitude was reduced from 
21.3±1.5pA to 0.5±0.2pA, with a changing level of 21.4±1.5pA (p=0.000692); and the mEPSCs 
frequency reduced from 5.2±0.2Hz to 0.4±0.1Hz, with a changing level of 4.9±0.3Hz 
(p=0.000612, N=10). There were statistically significant differences between group means as 
determined by one-way ANOVA: F (3, 35) = 52.903, p= 0.000196. (*, p≤0.05; **, p≤0.01; ***, 


















Table 6.1 Plethysmography data after drug treatment 
 BL 20min 40min 60min N 
Tidal V (ml·100g-1)      
CPS 0.39±0.02 0.38±0.02 0.38±0.02 0.38±0.02 5 
Morphine 0.35±0.05 0.25±0.01 0.22±0.01 0.23±0.01 12 
Morphine+CPS 0.37±0.02 0.28±0.01 0.28±0.01 0.29±0.01 11 
      
Frequency (Hz)      
CPS 1.8±0.0 1.8±0.0 1.8±0.0 1.8±0.0 5 
Morphine 2.0±0.1 0.6±0.0 0.5±0.0 0.5±0.0 12 
Morphine+CPS 2.1±0.0 1.0±0.0 1.1±0.0 1.5±0.0 11 
      
Minute V  
(ml·min-1·100g-1) 
     
CPS 41.69±2.52 40.96±2.68 40.87±3.21 40.93±2.66 5 
Morphine 42.09±2.40 8.67±0.54 6.05±0.36 7.35±0.40 12 

























Table 6.2 Survival data after chemical treatment 
 
  
 Morphine dose 
(mg/kg) 
48 68 88 108 128 140 150 170 
Group Outcome         
CPS + 
morphine  
Survived 7 7 9 8 6 3 1 0 
Dead 0 0 1 2 4 4 6 7 
Saline + 
morphine 
Survived 7 6 7 5 2 0 0 0 
Dead 0 1 3 5 8 7 7 7 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































7 GENERAL DISCUSSIONS 
We sought to discover certain common mechanisms of CRD from two animal models 
involving abnormalities in specific neurotransmission and neuronal excitability and tested the 
effectiveness of a novel treatment method to alleviate CRD. We have found that Mecp2R168X 
male mice shows an overall decrease in inhibitory synaptic signaling in XII/DMNV neurons. We 
have also found that the reduction of GABAAergic inhibition is significantly greater than 
glycinergic signaling. Thus, the RTT mice rely more on glycine than GABA to maintain the 
inhibitory system. In rats, morphine-induced CRD is obvious when measuring breathing activity. 
In the rats, LC neurons are strongly inhibited due to both hyperpolarization of the cells and lack 
of sufficient presynaptic glutamatergic input. Remarkably, the morphine-induced CRD and 
alterations of LC neuronal excitability caused by morphine treatment are treatable by the over-
the-counter cough medicine CPS. The CPS alleviates the morphine-induced CRD by blockade of 
GIRK channels in LC neurons and presynaptic glutamatergic cells. The CPS also increases 
glutamate release from presynaptic terminals by blocking presynaptic metabolic glutamate 
receptors. All these helps to ease neuronal hypo excitability during morphine exposure.  
Our results indicate that the CRD found in the RTT model and the morphine treated rats 
share similar behavioral and cellular phenotypes. Behaviorally, we have shown that both CRD 
models have decreased breathing tidal volume, reduced minute ventilation, and increased 
breathing frequency variation. Both types of CRD involve abnormalities in neurotransmission 
and neuronal excitability. Despite these similarities, specific cellular mechanisms are playing a 
part in these two CRD models. In the RTT model, the inhibitory synaptic signals are defective in 
XII/DMNV neurons, while lack of the excitatory neurotransmission and postsynaptic inhibition 




respiration regulation depends on an elaborate balance of excitation vs inhibition of brainstem 
neurons, and the CRD can take place when either is disrupted. 
Both inhibitory and excitatory neurotransmissions, together with the altered neuronal 
excitability, are known to be critical during CRD development. With respect to the inhibitory 
neurotransmission, it is known that defects in both GABA and glycine signaling are attributable 
to the CRD symptom in RTT mice (Mesuret, Dannenberg et al. 2018, Lozovaya, Nardou et al. 
2019). In comparison of these two, we have found that the glycine system seems better reserved 
in brainstem neurons than the GABA system. The presence of higher levels of endogenous 
glycine neurotransmitter and glycine receptors in RTT brainstem neurons than those for GABA 
signaling is encouraging as the glycine system seems to be an ideal target for correction of 
synaptic inhibition when the GABA system is badly impaired. It is possible that targeting on the 
glycine signaling provides a promising addition to current therapeutic strategy focusing on the 
GABA system. 
These dissertation studies have allowed us to identify several potential targets for 
pharmacological intervention. In the RTT model, deficiency of inhibitory neurotransmission is 
critical. At present, several potential counteractions are being attempted, mainly focusing on the 
GABA system (Abdala, Dutschmann et al. 2010, Voituron and Hilaire 2011, Zhong, Cui et al. 
2015, Zhong, Johnson et al. 2016, Zhong, Johnson et al. 2017). In addition to the GABA system, 
our new finding in this dissertation indicates that the glycine mediated neurotransmission seems 
to be another promising target for CRD treatment in RTT. Our results have shown that glycine 
signaling is impaired to a much less degree in RTT mice than the GABA system. The existing 
glycine and glycine receptor may allow brainstem neurons to maintain decent synaptic inhibition 




inhibitory neurons release both GABA and glycine with each excitation or firing. Such a co-
localization of two inhibitory neurotransmitters tends to enable the host neurons to perform their 
inhibitory function when one of the neurotransmitter systems is defective, which is not a surprise 
because such a conservational arrangement in the brainstem neurons is vital for systemic 
survival. By taking the advantage of the conservational arrangement in brainstem neurons, 
glycine seems more likely to be manipulated in RTT under CRD condition for several reasons: 
1) The glycine content is higher than GABA in the RTT model; 2) glycine is found sparsely in 
other brain areas; 3) there are selective agents acting on glycine uptake and receptor binding; 4) 
the GABA agonist-induced sedation may be avoided. It is possible that by focusing on enhancing 
glycinergic neurotransmission instead of GABA, more effective therapeutical modalities can be 
formulated to achieve better breathing improvement and avoid the side effects of the treatment 
such as sedation. 
The abnormal excitatory glutamatergic system is known to play a role in opioid-induced 
CRD. In this current study, we have found that blockade of GIRK channels with CPS improves 
morphine-induced CRD and alleviates the depression of LC neuronal excitability with morphine 
treatment. Such GIRK channel inhibition not only results in an increase in LC neuronal 
excitability, but also raises excitatory synaptic input by depolarization of excitatory presynaptic 
neurons. Thus, CPS appears to counteract morphine-induced LC cell inhibition by both pre- and 
postsynaptic mechanisms.  
A recent study from our lab suggests that CPS improves breathing dysfunction in Mecp2-null 
mice, where brainstem neurons tend to be overly excitable. The hyperexcitability of LC neurons 
can be improved with CPS. This is mediated by blocking GIRK channels in synaptic terminals 




channel inhibition on LC neurons (Johnson, Cui et al. 2020). Unlike glutamatergic neurons, the 
presynaptic GABAergic neurons in the dorsal tegmental nucleus (DTN) do not have functional 
GIRK channels (Johnson, Cui et al. 2020). As a result, the observed effect of CPS on LC neurons 
is inhibitory in the RTT model. Although the general effect of CPS is to depolarize individual 
neurons, its overall effect on a specific neuronal network depends on where in the soma, 
dendrites and/or synaptic terminals these cells express the GIRK channels, and whether or not 
the excitatory effect of CPS on a neuron is greater than the inhibitory synaptic input to the cell. 
It is worth noting that CPS seems to facilitate excitation more than inhibition in morphine-
induced CRD, and vice versa in the RTT model. How these apparently opposite effects take 
place is unclear. One possible mechanism would be that CPS has different affinity for various 
synaptic isoforms of GIRK channels on different types of neurons, which does not seem to be the 
case as our previous study has shown that CPS blocks GABAB receptors in presynaptic 
terminals, and facilitates GABA release (Johnson, Cui et al. 2020). Another possibility is that the 
proportion of active synaptic outputs from the excitatory and inhibitory neuronal networks 
becomes different after GIRK channel blockade. Supporting evidence for this scenario can be 
found in our previous studies showing that CPS causes inhibition of GABAergic neurons in the 
DTN instead of excitation, as these neurons do not show functional GIRK channel activity 
(Johnson, Cui et al. 2020). Furthermore, it is possible that the effect of GIRK channel inhibition 
depends on the state of membrane excitability, which is subject to each condition of RTT and 
morphine overdose. In the case of the hyperexcitability in a neuron from the RTT model, further 
excitatory input might have limited effect on the cell when its excitability has reached the ceiling 
or extreme level. Consequently, the inhibitory effect becomes predominant. Indeed, there is 




(Zhang, Johnson et al. 2016). In the case of morphine-induced CRD, on the other hand, 
brainstem neuronal inhibition is intensive and overwhelming. Under this condition, extra 
inhibitory input may not be as effective as the recruitment of additional excitatory input. 
Nevertheless, future studies are needed to reveal how CPS acts selectively on the excitatory and 
inhibitory systems in brainstem neurons.  
Although our studies suggest a potential approach to alleviate morphine-induced CRD via the 
GIRK channel mechanism, we must keep all potential side effects into consideration. Taking 
several medications along with CPS could potentially be at risk of developing adverse side 
effects. There are reports indicating that patients show dystonia when taking CPS together with 
different medicines (Linazasoro, Garmendia et al. 2000). Another study shows that CPS inhibits 
hERG channels to prolong the QT interval (Snyders 1999). In our preliminary studies, 
intraperitoneal injections of CPS (30 mg/kg) and morphine (10mg/kg) caused suspicious seizure 
attack in 2 of 7 rats, suggesting that a mixture of CPS and morphine should be used with 
precautions. Future dose-dependent and pharmacokinetic studies of CPS are necessary. Our use 
of CPS to treat CRD is one of a few studies that have tested the drug effects on behaviors other 
than cough. Clearly, all that we have found about CPS in these studies are still at the early stage, 
and more studies are warranted before preclinical and clinical trials. Overall, these results 
indicate that CPS seems to be an alternative drug for the treatment and prevention of opioid-
induced CRD, as respiratory stimulants that are now the only available agents for opioid 







These dissertation studies were aimed at addressing mechanisms of CRD. Our results from 
the RTT study indicate both GABA and glycine signaling co-exist in equal quantity in the 
presynaptic cells of XII and DMNV neurons from control mice. These presynaptic neurons were 
previously known as GABAergic. In the mouse model of RTT, an overall reduction of inhibitory 
neurotransmission is found in XII and DMNV neurons, while such a defect is much less severe 
in the glycinergic system as indicated by optogenetics, pharmacological electrophysiology and 
glycinergic synaptic currents. Thus, these two medullary neurons rely more on glycine than 
GABA in their inhibitory synaptic transmission. It is possible that GABA and glycine act in a 
mutual compensational way to maintain the inhibitory synaptic transmissions in the brainstem 
neurons. When one of them is deficient, the other can compensate. This is an evolutional strategy 
ensuring system survival, which is necessary for the brainstem where several vital functions are 
housed. The morphine-induced CRD study reveals that morphine treatment leads to CRD that 
can be alleviated by CPS. Examining cellular mechanisms, we have found that CPS blocks 
GIRK channels in LC neurons and their presynaptic glutamatergic neurons. These pre- and 
postsynaptic effects allow CPS to dampen morphine-induced depression in LC neuronal 
excitability. These studies in the RTT model and morphine-overdose model indicate that CRD 
occurs with impair in either neurotransmission or neuronal excitability in brainstem neuronal 
networks. So does it with either hyper- or hypo excitability of the brainstem neurons that are 
involved in respiratory regulations. The understanding of the cellular and molecular basis of 
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